Novartis Confidential Page 2of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 6
List o
f figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 9
Amendment 1 (29 -May-
2020)........................................................................................... 11
Protocol summary .............................................................................................................. 13
1Introduction ....................................................................................................................... 17
1.1 Background ............................................................................................................ 17
1.2 Purpose .................................................................................................................. 20
2Objectives and endpoints ................................................................................................... 21
2.1 Primary  estimands ................................................................................................. 22
2.2 Secondary  estimands
............................................................................................. 23
3Study  design ...................................................................................................................... 24
4Rationale ............................................................................................................................ 25
4.1 Rationale for stud y design ................................ ................................ ..................... 25
4.2 Rationale for dose/regimen and duration of treatment .......................................... 25
4.3
Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 26
4.4 Purpose and timing of interim anal yses/design adaptations ................................ ..26
4.5 Risks and benefits .................................................................................................. 26
5Study  Population ................................ ................................ ................................ ............... 30
5.1 Inclusion criteria .................................................................................................... 30
5.2 Exclusion criteria ................................................................................................... 30
6Treatment ........................................................................................................................... 31
6.1 Study  treatment ...................................................................................................... 31
6.1.1 Investigational and control drugs .......................................................... 31
6.1.2 Additional study  treatments .................................................................. 31
6.1.3 Supply  of study  treatment ..................................................................... 31
6.1.4 Treatment arms/group ........................................................................... 32
6.2 Other treatment(s) .................................................................................................. 32
6.2.1 Concomitant therap y
............................................................................. 32
6.2.2
Prohibited medication ........................................................................... 32
6.3 Participant numbering, treatment assignment, randomization .............................. 33
6.3.1 Participant numbering ........................................................................... 33
6.3.2 Treatment assignment, randomization .................................................. 33

Novartis Confidential Page 3of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
6.4 Treatment blinding ................................ ................................ ................................ .33
6.5 Dose escalation and dose modification.................................................................. 34
6.6 Additional treatment guidance ............................................................................... 34
6.6.1 Treatment compliance ........................................................................... 34
6.6.2 Recommended treatment of adverse events .......................................... 34
6.6.3 Emergency  breaking of assigned treatment code .................................. 34
6.7 Preparation and dispensation ................................................................................. 35
6.7.1 Handling of study  treatment .................................................................. 35
6.7.2 Instruction for prescribing and taking s tudy treatment ......................... 36
7Informed consent procedures
............................................................................................ 36
8
Visit schedule and assessments ......................................................................................... 37
8.1 Screening ............................................................................................................... 41
8.1.1 Information to be collected on screening failures ................................. 41
8.2
Participant demographics/other baseline characteristics ....................................... 41
8.2.1 Demographic/baseline characteristics information
............................... 41
8.2.2 Prior and concomitant medications....................................................... 41
8.3 Efficacy .................................................................................................................. 42
8.3.1 Clinical status (9 -point ordinal scale) ................................................... 42
8.3.2 Vital signs and ox ygen saturation and use ............................................ 42
43
43
8.3.5 Appropriateness of efficacy  assessments .............................................. 43
8.4 Safety ..................................................................................................................... 43
8.4.1 Laboratory  evaluations .......................................................................... 44
8.4.2 Physical exam
........................................................................................ 44
8.4.3 Height, weight ....................................................................................... 45
8.4.4 Electrocardiogram (ECG) ..................................................................... 45
8.4.5 Pregnancy  and assessments of fertility ................................................. 45
8.4.6 Chest x -ray or CT scan .......................................................................... 45
8.4.7 Appropriateness of safety  measurements .............................................. 45
8.5
Additional assessments.......................................................................................... 46
8.5.1 SARS -CoV -2 nasopharyngeal samples ................................................. 46
46
46
46
46

Novartis Confidential Page 4of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
47
47
9Study  discontinuation and completion .............................................................................. 47
9.1
Discontinuation and completion............................................................................ 47
9.1.1 Study  treatment discontinuation and study  discontinuatio n.................. 47
9.1.2 Withdrawal of informed consent ........................................................... 48
9.1.3 Lost to follow -
up................................................................................... 49
9.1.4 Early study termination by the sponsor ................................................. 49
9.2 Study  completion and post -study  treatment .......................................................... 49
10Safety  monitoring and reporting ........................................................................................ 50
10.1 Definition of adverse events and reporting requirements ...................................... 50
10.1.1 Adverse events ...................................................................................... 50
10.1.2 Serious adverse events .......................................................................... 51
10.1.3 SAE reporting
........................................................................................ 52
10.1.4 Pregnancy  reporting .............................................................................. 53
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 53
10.2 Additional Safety  Monitoring ................................................................................ 54
10.2.1 Liver safety  monitoring ......................................................................... 54
10.2.2 Data Monitoring Committee ................................................................. 54
11Data Collection and Database management ................................ ................................ ......55
11.1 Data collection....................................................................................................... 55
11.2 Database management and quality  control ................................ ............................ 55
11.3 Site monitoring ...................................................................................................... 56
12Data analy sis and statistical methods ................................ ................................ ................ 56
12.1 Analy sis sets .......................................................................................................... 57
12.2 Participant demographics and other baseline characteristics ................................. 57
12.3 Treatments ............................................................................................................. 57
12.4 Analy sis of the primary  endpoint(s)/estimand(s) .................................................. 57
12.4.1 Definition of primary  endpoint(s)/estimand(s) ..................................... 57
12.4.2 Statistical model, hy pothesis, and me thod of anal ysis.......................... 58
12.4.3 Handling of remaining intercurrent events of primary  estimand
.......... 58
12.4.4 Handling of missing values not related to intercurrent event ............... 58
12.4.5 Sensitivity  analy ses for primary  endpoint/estimand ............................. 58
12.4.6 Supplementary  anal ysis......................................................................... 58
12.4.7
Supportive analy ses............................................................................... 58
12.5 Analy sis of secondary  endpoints/estimands .......................................................... 59

Novartis Confidential Page 5of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
12.5.1 Key secondary  endpoint ................................ ................................ ........ 59
12.5.2 Other Secondary  objectives and endpoints ........................................... 59
12.5.3 Safety  endpoints .................................................................................... 59
60
60
61
12.6 Interim anal yses..................................................................................................... 61
12.7
Sample size calculation.......................................................................................... 61
12.7.1 Primary  endpoint(s) ............................................................................... 61
12.7.2 Secondary  endpoint(s) ........................................................................... 62
13Ethical considerations and administrative procedures ...................................................... 63
13.1 Regulatory
 and ethical compliance ........................................................................ 63
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. 63
13.3 Publication of study  protocol and resul ts............................................................... 63
13.4 Quality  Control and Quality  Assurance ................................................................. 63
14Protocol adherenc e
............................................................................................................ 64
14.1 Protocol amendments ............................................................................................. 64
15References ......................................................................................................................... 65
16Appendices ................................ ................................ ................................ ........................ 70
16.1 Appendix 1: Ordinal Scale Determination ............................................................ 70
70
16.3 Appendix 3: L
iver event and laboratory  trigger definitions & follow -up 
requirements .......................................................................................................... 71

Novartis Confidential Page 6of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
List of tables
Table 2-1 Objectives and related endpoints .......................................................... 21
Table 6
-1 Canakinumab dose b y body weight ...................................................... 31
Table 6
-2 Investigational and control drug............................................................ 31
Table 8
-1 Assessment and Procedures Schedule (Baseline to 18- week safet y 
follow up)13........................................................................................... 38
Table 8
-2 Clinical status (9 -point ordinal scale) ................................................... 42
47
Table 10
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... 54
Table 12
-1 Power for primary  analy sis under vary ing assumptions (sample 
size = 450) ............................................................................................. 62
Table 12
-2 Power for key  secondary  anal ysis (sample size = 450) ......................... 62
Table 16-1 Liver event and laboratory  trigger definitions ...................................... 71
Table 16
-2 Follow up requirements for liver laboratory  triggers ............................ 72
List of figures
Figure 3 -1 Study  design .......................................................................................... 25

Novartis Confidential Page 7of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
List of abbreviations
AE Adverse Event
ACE2 Angiotensin -converting enzy me 2
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
ANC Absolute neutrophil count
ARDS Acute respiratory distress syndrome
AST Aspartate Aminotransferase
ASTCT American society for transplantation and cellular therapy
BUN Blood Urea Nitrogen
CFR Case fatality rate
CMO&PS Chief Medical Office and Patient Safety
CoV Coronaviruses
COVID -19 Coronavirus disease 2019
CRF Case Report/Record Form (paper or electronic)
CRP C-reactive protein
CRS Cytokine release syndrome
CT Scan Computed tomography scan
DMC Data Monitoring Committee
ECG Electrocardiogram
ECMO Extracorporeal membrane oxygenation
EDC Electronic Data Capture
EMA European medicines agency
EOI End of Infusion
FAS Full analy sis set
FDA Food and Drug Administration
FiO 2 Fraction of inspired ox ygen
GCP Good Clinical Practice
GGT Gamma -glutam yl transferase
hr Hour
i.v./IV intravenous
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use
ICU Intensive care unit
IEC Independent Ethics Committee
IL Interleukin
IL-1R IL-1 receptor

Novartis Confidential Page 8of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
IN Investigator Notification
IRB Institutional Review Board
IRT Interactive Response Technology
ITT Intent to treat
LLOQ lower limit of quantification
MedDRA Medical dictionary for regulatory activities
mg milligram (s)
mL milliliter(s)
PaO 2 Partial pressure of oxygen
PBO Placebo
PCR Polymerase chain reaction
RRT Renal replacement therapy
s.c. subcutaneous
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SARS -CoV-2 Severe Acute Respirator y Syndrome Coronavirus -2
SOC Standard of care
SpO 2 Peripheral capillar y oxygen saturation
SUSAR Suspected Unexpected Serious Adverse Reaction
ULN upper limit of normal
WHO World Health Organization
WoC Withdrawal of Consent

Novartis Confidential Page 9of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Glossary  of terms
Additional 
treatmentMedicinal products that may be used during the clinical trial as described in the protocol, 
but not as an investigational medicinal product (e.g. any background therapy)
Assessment A procedure used to generate data required by the study
Biologic Samples A biological specimen including, for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study participant
Cohort A specific group of participants fulfilling certain criteria and generally treated at the same 
time
Control drug A study drug (active or placebo) used as a co mparator to reduce assessment bias, 
preserve blinding of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigational drug
Dosage Dose of the study treatment given to the participant in a time unit (e.g. 100 mg once a 
day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study data using 
data collection systems, such as W eb-based applications, interactive voice response 
systems and c linical laboratory interfaces. EDC includes the use of Electronic Case 
Report Forms (eCRFs) which are used to capture data transcribed from paper source 
forms used at the point of care
End of the clinical 
trialThe end of the clinical trial is defined as the last visit of the last participant or at a later 
point in time as defined by the protocol
Enrollment Point/time of participant entry into the study at which informed consent must be obtained 
Estimand A pre cise description of the treatment effect reflecting the clinical question posed by the 
trial objective. It summarizes at a population -level what the outcomes would be in the 
same patients under different treatment conditions being compared. Attributes of a n 
estimand include the population, variable (or endpoint) and treatment of interest, as well 
as the specification of how the remaining intercurrent events are addressed and a 
population -level summary for the variable.
Healthy volunteer A person with no kn own significant health problems who volunteers to be a study 
participant
Intercurrent events Events occurring after treatment initiation that affect either the interpretation or the 
existence of the measurements associated with the clinical question of in terest.
Investigational 
drug/ treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Mis-randomized 
participantsMis-randomized participants are those who were not qualified for randomization and who 
did not take study treatment, but have been inadvertently randomized into the study 
Other treatment Treatment that may be needed/allowed during the conduct of the stud y (i.e. concomitant 
or rescue therapy)
Part A sub -division of a study used to evaluate specific objectives or contain different 
populations. For example, one study could contain a single dose part and a multiple 
dose part, or a part in participants with e stablished disease and in those with newly-
diagnosed disease
Participant A trial participant (can be a healthy volunteer or a patient)
Participant number A unique number assigned to each participant upon signing the informed consent. This 
number is the d efinitive, unique identifier for the participant and should be used to 
identify the participant throughout the study for all data collected, sample labels, etc.
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) which are 
described in the Protocol. Periods define the study phases and will be used in clinical 
trial database setup and eventually in analysis
Personal data Participant information collected by the Investigator that is coded and transferred to 
Novartis for the purpose of the clinical trial. This data includes participant identifier 
information, study information and biological samples.

Novartis Confidential Page 10of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Premature 
participant 
withdrawalPoint/time when the participant exits from the study prior to the planned completion of all 
study drug administration and/or assessments; at this time all study drug administration 
is discontinued and no further assessments are planned
Randomization 
numberA unique identifier assigned to each randomized participant
Screen Failure A participant who did not meet one or more criteria that were required for participation in 
the study
Source 
Data/DocumentSource data refers to the initial record, document, or primary location from where data 
comes. The data source can be a database, a dataset, a sprea dsheet or even hard -
coded data .
Start of the clinical 
trialThe start of the clinical trial is defined as the signature of the informed consent by the 
first participant
Study treatment Any drug or combination of drugs or intervention administered to the study participants 
as part of the required study procedures; includes investigational drug(s), control(s) or 
background therapy
Study treatment 
discontinuationWhen the participant permanently stops taking any of the study drug(s) prior to the 
defined st udy treatment completion date (if any) for any reason; may or may not also be 
the point/time of study discontinuation 
Treatment 
arm/group A treatment arm/group defines the dose and regimen or the combination and may 
consist of 1 or more cohorts.
Treatm entof 
interestThe treatment of interest and, as appropriate, the alternative treatment to which 
comparison will be made. These might be individual interventions, combinations of 
interventions administered concurrently, e.g. as add-on to standard of care, or might 
consist of an overall regimen involving a complex sequence of interventions. This is the 
treatment of interest used in describing the related clinical question of interest, which 
might or might not be the same as the study treatment.
Variable
(or endpoint)The variable (or endpoint) to be obtained for each participant that is required to address 
the clinical question. The specification of the variable might include whether the 
participant experiences an intercurrent event.
Withdrawal of 
study co nsent 
(WoC)Withdrawal of consent from the study occurs only when a participant does not want to 
participate in the study any longer and does not allow any furth er collection of personal 
data

Novartis Confidential Page 13of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Protocol summary
Protocol number CACZ885D2310
Full Title Phase 3 multicenter, randomized, double -blind, placebo -controlled study to 
assess the efficacy  and safety of canakinumab on cytokine release 
syndrome in patients with COVID- 19-induced pneumonia (CAN -COVID)
Brief title Study of efficacy and safety of canakinumab treatment for CRS in 
participants with COVID -19-induced pneumonia
Sponsor and
Clinical PhaseNovartis
Phase III
Investigation type Drug
Study type Interventional
Purpose and 
rationaleThe purpose of this study is to evaluate the efficacy and safety of 
canakinumab forthe treatment of cytokine release syndrome (CRS) in 
patients with COVID- 19-induced pneumonia.
As of March 28, 2020, coronavirus disease 2019 (COVID -19) has been 
confirmed in 629,355 people worldwide. The mortality rate has been 
reported to be approximately 3.7%, compared with a mortality rate of less 
than 1% from influenza (Mehta et al 2020 ). There is an urgent need for 
effective treatment .
Accumulating evidence suggests that patients develop severe acute 
pneum onia due to COVID -19 with c ytokine release syndrome (CRS) . 
Currently, there is no clinical experience with canakinumab in the treatment 
of CRS, pneumonia or SARS -CoV-2 infection. However, the c ytokine 
profiling of patients with severe COVID -19 that includes elevated levels of 
interleukin (IL) -2, IL-7, IL-6, IL-1, granulocyte -colony  stimulating factor, 
interfer on-γ inducible protein 10, monocy te chemoattractant protein 1, 
macrophage inflammatory protein 1-α, tumor necrosis factor -α and other 
pro-inflammatory  cytokines suggests that canakinumab could improve 
patient outcomes (Mehta et al 2020 ; Zhou et al 2020 ).
Primary Objective To demonstrate the benefit of canakinumab + SOC in increasing the chance 
of survival without ever requiring invasive mec hanical ventilation among 
patients with COVID- 19-induced pneumonia and CRS
Secondary 
ObjectivesTo demonstrate the benefit of canakinumab in reducing 4 -week case 
fatality rate (CFR) among patients with COVID- 19-induced pneumonia and 
CRS regardless of other subsequent clinical interventions
To evaluate change from baseline in clinical serologic measurements 
related to CRS in COVID- 19patients with pneumonia
To evaluate safety of canakinumab in patients with COVID -19-induced 
pneum onia and CRS 
Study design This is a Phase 3, multicenter, randomized, double -blind, placebo -controlled 
study to assess the efficacy and safety of canakinumab in patients with 
COVID -19-induced pneumonia and CRS. The study will enroll patients to 
canakinumab or placebo, in ad dition to standard of care per local practice, 
which may include anti -viral treatment, cortico steroids and /orsupportive 
care. The total trial duration will be 126 days after the canakinumab or 
placebo dose. Safety will be closely monitored with an internal Novartis 
DMC during the study.

Novartis Confidential Page 14of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Study population Approximately 450 patients with diagnosed COVID -19-induced pneumonia 
and CRS will be randomized to canakinumab or placebo in a 1:1 ratio
Key Inclusion 
criteria1.Male or female
2.Adults ≥ 18 years old ( for US only: patients ≥ 12 years old)
3.Body weight ≥40 kg
4.Informed consent must be obtained prior to participation in this study. For 
US patients 12 -< 18 years old; parent/guardian consent must be obtained 
and assent if applicable.
5.Clinically diagnosed with SARS -CoV-2 virus by PCR or by other 
approved diagnostic methodology within 7 days prior to randomization
6.Hospitalized with COVID -19-induced pneumonia evidenced by chest x-
ray or CT scan (taken within 5 days prior to randomizatio n) with pulmonary 
infiltrates
7.SpO2≤ 93% on room air ,or arterial ox ygen partial pressure (Pa O2)/ 
fraction of inspired ox ygen (Fi O2) < 300mmHg (1mmHg=0.133kPa) 
(corrective formulation should be used for higher altitude regions (over 
1000m ))
8.C-reactive protein ≥20 mg/L or ferritin level ≥600 µg/L
Key Exclusion 
criteria1.History of hypersensitivity to canakinumab or to biologic drugs
2.Intubated and on mechanical ventilation (invasive) at time of 
randomization
3.Treatment with immunomodulators or immunosuppressant drugs, 
including but not limited to tocilizumab, TNF inhibitors and anti- IL-17 agents 
within 5 half -lives or 30 days (whichever is longer) prior to randomization 
with the exception of anakinra which is e xcluded within 5 half -lives only. 
Note: Immunomodulators (topical or inhaled) for asthma and atopic 
dermatitis and corticosteroids (any route of administration) are permitted
4.Suspected or known untreated active bacterial, fungal, viral, or parasitic 
infection with the exception of COVID -19
5.Neutropenia withANC <1000/mm3
6.Any serious medical condition or abnormality of clinical laborator y tests 
that, in the investigator’s judgment, precludes the patient’s safe participation 
in and completion of the s tudy
7.In the opinion of the investigator, progression to death is imminent and 
highly likely within the next 24 hours, irrespective of the provision of 
treatments
8.Current p articipation in any other investigational trials
Study treatment Arm 1: Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60 -80
kg,or 750 mg for >80kgin 250 mL of 5% dextro se infused IV over 2 hours
Arm 2: 250 mL of 5% dextrose infused IV over 2 hours
Canakinumab or placebo infusions will be prepared and blinded by an 
unblinded pharmacist ordesignated staff member .
Treatment of 
interestRandomized canakinumab or placebo as described above. In addition, all 
patients will receive SOC per local practice for the treatment of COVID -19-
induced p neum onia. The SOC may  include anti -viral treatment, 
cortico steroids and /orsupportive care.

Novartis Confidential Page 17of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
1 Introduction
1.1 Background
Coronavirus disease 2019 ( COVID -19) is a global pandemic (Gorbalen ya et al 2020, WHO 
2020a )
. What started as an epidemic of COVID -19 cases with unexplained lower respiratory  
tract infections first detected in Wuhan, the largest metropolitan area in China's Hubei province, 
and reported to the World Health Organization ( WHO )Country  Office in Chin a on December 
31, 2019 has now spread globall y with 629,355 confirmed cases worldwide and 28,963 deaths 
reported (March 28, 2020; Worldometers 2020 ).As of March 12, 2020, the mortality  rate was 
calculated at approx imately  3.7%, compared with a mortalit y rate of less than 1% from 
influenza. Currently , there are no approved treatments nor vaccines, and so there is an urgent 
need for effective treatment (Mehta et al 2020).
COVID -19 is caused by  the Severe Acute Respiratory  Syndrome Coronavirus
-2 (SARS -CoV -
2) and belongs to family  coronoviridae (Ahn et al 2019, Gorbalen ya et al 2020 ,WHO 2020a ).
Coronaviruses (CoV) are positive -stranded RNA viruses with a crown -like appearance under 
an electron microscope due to the presence of spike gly coproteins on the viral envelope. They  
are a large family  of viruses that cause illness ranging from the common cold to more severe 
diseases ,such as the severe acute respiratory  syndrome coronavirus (SARS -CoV) from 2002 
and the Middle East respiratory s yndrome coronavirus (MERS -CoV) from 2012 (MERS). Like 
SARS -CoV and MERS -CoV , it is believed that SARS -CoV -2 moved from bats to an 
intermediate host (possibly  a
 Malayan Pangolin, which shares 91% nucleotide identity ) and 
then to humans ( Ahn et al 2019 ,Gorbalen ya et al 2020 ).
Patients infected with SARS -CoV -2present with a wide range of clinical severity  varying from 
asymptomatic to a severe form of interstitial pneumonia, which may progress towards acute 
respiratory  distress syndrome (ARDS) and/or multi organ failure and death. The clinical 
symptoms of COVID -19 patients include fever, cough, fatigue, loss of smell, and shortness of 
breath within 2-14 days after exposure (CDC 2020). SARS -CoV - 2 uses the same receptor as 
SARS -CoV, angiotensin -converting enzyme 2 (ACE2) and mainl y spreads through the 
respiratory  tract (Hoffmann et al 2020 ,Xu H et al 2020, Zhao D et al 2020 ). Although currently , 
the pathogenesis of the pulmonary  manifestations of COVID -19 remains poorly  defined and 
knowledge of factors affecting disease severity  is limited, underly ing illnesses such as diabetes, 
cardiovascular diseases, hypertension, cancer and older age are associated with poorer outcome 
(Huang et al 2020, Chen et al 2020, Guan et al 2020). Cytokine profiling of patients with severe 
COVID -19 includes elevated levels of interleukin (IL) -2, IL -7, IL -6, IL -1, granulocy te-colon y 
stimulating factor, interferon -γ inducible protein 10, monocy te chemoattractant protein 1, 
macrophage infl ammatory  protein 1 -α and tumor necrosis factor -α (Wang et al 2020 ,Mehta et 
al 2020, Wan et al 2020 , Liu et al 2020, Zhou et al 2020 ,Diao et al 2020 ).
COVID -19 associated pneumonia and ARDS have raised questions about the possible role of a 
cytokine storm in pathogenesis of SARS -CoV -2. Profound lung injury , in particular that of type 
II alveolar epithelial cells that express the viral entry  receptor, ACE2, has the potential to 
activate intracellu lar pathogen sensing platforms called inflammasomes (Chen et al 2019, Xu 
H et al 2020 ,Zhao and Zhao 2020 )
.Activated inflammasomes initiate cleavage of pro -IL-1βto 
active IL-
1β, resulting in a robust pro-inflammatory  response with activation and subsequent 
recruitment of neutrophils and macrophages with the normal physiological role of controlling 

Novartis Confidential Page 18of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
viral infection (Bauernfeind et al 2011 ,Zhao and Zhao 2020 ).An overexuberant inflammatory  
response as the result of accumulation of innate immune cells results in vascular leakage, 
pulmonary  edema, h ypoxia culminating in ARDS (Leff et al 1994 , Olman et al 2004 ,Ganter et 
al 2008). Furthermore, severe COVID -19 patients are reported to exhibit increased circulating 
levels of IL -
1βand IL -6 that appears to negativel y impact T cell numbers while also increasing 
the expression of checkpoint inhibitor programmed death 1 on T 
cells (Diao et al 2020 ,Zheng 
et al 2020). In contrast, non-severe patients that recover show decrea sed IL-6, IL-10 and 
interferon -
γin circulation, suggesting resolving inflammation and the recruitment of antibody -
secreting B cells, TFHcells and activated CD4+ and CD8+ T cells, together with IgM and IgG 
SARS -CoV -2-binding antibodies, in the patient’s blood before the resolution of symptoms 
(Thevarajan et 
al 2020). This strongl y suggests that lack of resolution of inflammation is a 
hallmark of severe COVID -19 patients and given that IL -
1βis a key  regulator of inflammation 
in a variet y of chroni c conditions such as cardiovascular disease, autoinflammatory  diseases, 
and cancer (Toldo et al 2014 ,Fang et al 2018 ,Mantovani et al 2018), it strongl y suggests arole 
of IL-1βin non -resolving inflammation following SARS -CoV -2 in severe COVID -19 patients 
with pneumonia and ARDS.
Numerous clinical and preclinical studies demonstrate that inflammasome -derived IL -
1βplays
a critical role in the development of sterile inflammation during ARDS and contributes to acute 
lung injury  
(Patton et al 1995, Kolb et al 2001 ,Ganter et al 2008). IL- 1β is significantly  elevated 
in bronchoalveolar fluid and plasma in patients with ARDS compared to healthy controls and 
is associated with poor clinical outcomes (Meduri et al 1995, Park et al 2001, Bouros et al 2005).
Patients with ARDS following infection with other coronaviruses such as MERS -CoV and 
SARS -CoV exhibit a high IL-
1βsignature that includes downstream mediators, IL- 6 and IL-8 
(He et al 2007, Lau et al 2013 ,Min et al 2016, Alosaimi et al 2020), strongl y indicating that 
inflammation -driven ARDS in severe COVID -19 patients might be driven by  IL-1β.
The Spanish influenza pandemic of 1918 and seasonal outbreaks of influenza sub -strains have 
both been documented to cause ARDS in mice and primates with an acute pulmonary 
inflammatory  response that includes neutrophils and macrophages and high levels of IL-
1βin 
bronchoalveolar lavage and plasma (Meduri et al 1995, Park et al 2001, Beigel et al 2005,
Bouros et al 2005 ,Tumpey  et al 2005 ,Kobasa et al 2007 ,Perrone et al 2008
). In mice that lack 
IL-1R, the AIM-2 inflammasome -the acute pathological granulocy tic response -is markedly  
reduced, and attenuated lung injury  and significant improvement in survival against influenza 
A viruses are observed, while viral burden in the lung is not altered (Schmitz et al 2005 ,Zhang 
et al 2017). Blockade of IL- 1βeither via administration of recombinant IL-1R antagonist or 
blocking antibody  prevented an influenza -driven inflammatory  response, reducing the 
development of pulmonary  fibrosis and acute lung damage (Gasse et al 2007 ,Kim et al 2015 ). 
These data strongl y indicate that IL-1βis akey cytokine orchestrating acute lung injury  and 
inflammatory  response (Kim et 
al 2015) contributing to ARDS following infection with 
respiratory viruses other than SARS -CoV -
2.
CAR -T cell therap y is a highl y specific and effective therap y for a subset of B cell malignancies 
(Porter et al 2015, Schuster et al 2017). However, broader use of this powerful approach is 
limited by potentially  lethal toxicities, such as the induction of severe cytokine release 
syndrome (CRS) and neurotox icity. Characteristics of CRS include fever, fatigue, headache, 
encephalopath y, hypotension, 
tachy cardia, coagulopathy , nausea, capillary  leak, and multi-

Novartis Confidential Page 19of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
organ dysfunction (Porter et al 2018) and is graded using theASTCT CRS grading criteria 
(Appendix 2).The reported incidence of CRS after CAR - Tcell therapy  ranges from 50% to 
100%, with 13% to 48% of patients experiencing the severe or life-threatening form. Serum 
levels of inflammatory  cytokines are elevated, particularl y IL-6, and IL-6R blockade using 
tocilizumab has been approved for the treatment of severe or life-threatening CAR -T cell-
induced CRS (Le et al 2018, Kotch et al 2019). Given the increased levels of IL-6 in COVID -
19 patients and the role of IL -6 in SARS -associated ARDS (Wang et al 2020 ,Mehta et al 2020 ,
Wan et 
al 2020, Liu et al 2020 ,Zhou et al 2020, Diao et al 2020 ), twenty -one patients with 
severe or critical COVID -19 pneumonia were treated recently  with tocilizumab IV (400 mg) 
plus SOC that consisted of lopinavir, methy lprednisolone, other symptom relievers, and oxygen 
therap y as recommended by the Diagnosis and Treat ment Protocol for Novel Coronavirus 
Pneumonia (Sixth Edition) (Xu X et al 2020). No deaths were reported, and after tocilizumab 
treatment, 75% of patients exhibited lowered O2 intake, 90% of patients showed signific ant 
improvement in lung opacities and 85% of patients showed significant decrease in C
-reactive 
protein ( CRP )levels (Xu X et al 2020 ). Recentl y, it has been shown that monocyte -derived IL -
1βand IL- 6 (downstream ofIL-1β) differentially  regulate CRS and neurotoxicity  associated 
with CAR -T therap y, with the IL-
1 receptor antagonist anakinra abolishing both CRS and 
neurotoxicity , resulting in substantially  extended leukemia -free survival (Giavridis et al 2018,
Norelli et 
al 2018 ). The IL-6R blockade with tocilizumab in alleviating COVID -19 sy mptoms 
together with the role of IL-1β, upstream of IL-6, in the pathop hysiology  of CAR -T-induced 
CRS strongly suggests that IL-b blockade might alleviate the cytokine storm following COVID -
19 that promotes pneumonia, ARDS and worse outcome.
Canakinumab is a high-affinity  human monoclonal anti-human IL-1β antibody  of the IgG1 /k 
isoty pe which is marketed and under ongoing development for the treatment of IL-1β driven 
inflammatory  and oncologic diseases. By binding specificall y to human IL-1β, canakinumab 
blocks the interaction of IL-1β with the IL-1 receptor (IL-1R), leading toinhibition of its 
downstream targets, thereby  preventing IL-1β-induced gene activation and the production of 
downstream inflammatory  mediators such as IL-6 and CRP. Canakinumab, first registered for 
the treatment of cryopyrin-associated auto inflammatory syndrome (CAPS )in the United States 
on 17 Jun 2009, ameliorates IL-1β -mediated inflammation and was shown recentl y in thePhase 
3CANTOS trial to significantly reduce major adverse cardiovascular events and lung cancer 
incidence and mortality  (Ridker et al 2017 ) .
Taken together, evidence including: (1) the central role of IL-1βand IL- 1 β-driven inflammation 
in the pathoph ysiology  of ARDS; (2) the increased morbidity  and mortality  of COVID -19
patients with chronic underly ing inflammatory  conditions (cardiovascular disease, diabetes ) 
who develop pneumonia; (3) the CANTOS -trial data in cardiovascular disease and lung cancer; 
and (4) the excellent safety  profile of canakinumab, supports the urgen t need to evaluate 
canakinumab in COVID -19 patients with pneumonia and cytokine release syndrome in the 
setting of SARS -CoV -2 infection.
Based on recent observations in severe and non-severe COVID -19patients and historical data 
(Meduri et al 1995, Park et al 2001, Beigel et al 2005, Bouros et al 2005, Tum pey et al 2005,
He et al 2007 ,Kobasa et al 2007 , Perrone et al 2008 , Lau et al 2013 ,Min et al 2016 ,Alosaimi 
et 
al 2020, Thevarajan et al 2020 )with other infectious pathogens that cause respiratory  distress, 
 

Novartis Confidential Page 21of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary Objective
To demonstrate the benefit of canakinumab + 
standard of care ( SOC) in increasing chance of 
survival without ever requiring invasive 
mechanical ventilation among patients with 
COVID -19-induced pneumonia and CRSEndpoint for primary objective :
Clinical response, defined as survival without 
ever requiring invasive mechanical ventilation 
from Day  3 (inclusive) up to Day 29 (inclusive).
Secondary Objective(s)
To demonstrate the ben efit of canakinumab in 
reducing 4 -week case fatality rate (CFR) among 
patients with COVID- 19-induced pneumonia and 
CRS regardless of other subsequent clinical 
interventionsEndpoint(s) for secondary objective(s) :
COVID -19-related death during the 4 -week
period after study treatment
To evaluate change in clinical serologic 
measurements related to CRS in COVID- 19 
patients with pneumoniaAdjusted geometric mean ratio to baseline
overtime up to Day29 in the following clinical 
chemistry  measurements:
CRP
Serum ferritin
D-dimer
To ev aluate safety of canakinumab in patients 
with COVID -19-induced pneumonia and CRSNumber of participants with Adverse Event (AE), 
serious adverse events (SAE), 
clinically significant changes in labor atory 
measures, and vital signs

Novartis Confidential Page 22of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Objective(s) Endpoint(s)
2.1 Primary  estimands
The primary  clinical question of interest is: Does canakinumab + SOC increase the chance of 
survival without ever requiring invasive mechanical ventilation among patients with COVID -
19-induced pneumonia and CRS after start of treatment, regardless of other subsequent clinical 
interventions?
The justification for this primary  estimand is that it captures the clinical outcome of most 
interest after canakinumab administration, which reflects also any effects of additional 
subseque nt interventions potentially  due to such clinical decision. In the ongoing 
COVID -19 
pandemic with evolving treatment guidelines and healthcare system burdens, this primary 
estimand is deemed better to reflect actual clinical practices. In addition, the IV delivery  of 
canakinumab is expected to result in a fast decrease in pharmacologically  active IL-1β and to 
reduce L-1β signaling to marginal levels within hours. However, clinical signs or symptoms 
within the 24 hours after treatment may not necessarily ref lect such pharmacological effect yet. 
Therefore, only  clinical status starting from Day 3 will be considered for the primary endpoint.
The primary  estimand includes the following components:
Population: Patients with COVID-19- induced pneumonia and CRS .
Endpoint: Clinical response, defined as survival without ever requiring invasive mechanical 
ventilation from Day 3(inclusive) up to day 29(inclusive) . A patient will be defined as a non-
responder if the wors tclinical status at an y time from Day3 (inclusiv e) up to Day 29 (inclusive) 
is requiring invasive mechanical ventilation or death (category  6,
7 or 8 on the WHO 9-point
ordinary  scale of clinical status )
.

Novartis Confidential Page 23of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Treatment of interest: The randomized study treatment (canakinumab or placebo) added onto 
SOC with or without additional subsequent clinical interventions.
Handling of intercurrent events :
The treatment policy  strategy  will b e adopted for primary  anal ysis.
Clinical interventions (e.g. mechanical ventilator, oxy gen, intubation) newly  administered 
as escalated SOCs corresponding to the progression of disease are integrated in efficacy  
evaluation based on the 9-category  ordinal scale of clinical status.
Other n ew or change in strength of concomitant interventions will not be adjusted for 
primary  anal ysis.
Early discontinuation from study  or lost to follow up before Day  29: A patient will be 
considered as re sponder if did not require invasive mechanical ventilati
on any  time on or 
after Day 3andmeets at least one of the following two criteria :
1. The patient was discharged from hospital with clini cal status of 0 or 1
2.The last clinical status was on Day  15 or later and better than baseline
Patient will otherwise be considered as non -responder.
Summary measure: Difference and Odds -ratio comparing response rates in the canakinumab 
and placebo groups.
2.2 Secondary estimands
The key secondary  clinical question of interest in this study  is: Does the administration of 
canakinumab reduce 4-week mortalit yamong patients with COVID -19-induced pneumonia and 
CRS, regardless of other subsequent clinical interventions?
The justificatio n for this secondary  estimand is that mortality currently  represents the main 
epidemiological and clinical concern for COVID -
19 patients and accumulating evidences 
suggest coexistence of CRS with severe COVID -19-induced pneumonia. Subsequent clinical 
interventions, including intensive cares when a patient become terminally ill, reflect actual 
clinical 
practices, whose needs, scope and effectiveness could potentially  be related to the 
earlier decision of canakinumab admin istration.
The key  secondary  estimand includes the following components:
Population: Patients with COVID-19 -induced pneumonia and CRS .
Endpoint: COVI D-19-related death during the 4- week period after study  treatment
Treatment of interest: The randomized stu
dy treatment (canakinumab or placebo) added onto 
SOC with or without additional sub sequent clinical interventions.
Handling of remaining intercurrent events:
The treatment policy  strategy  will be adopted f or this key  secondary  anal ysis.
Effect of other sub sequent clinical interventions will not be adjusted
Early study discontinuation or l ost to follow -up before Day  29: A patient will be 
considered as survivor if discharged from hospital
with clinical status of 0 or 1
Otherwise, the patient will not be inclu ded in this key secondary  analy sis.

Novartis Confidential Page 24of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Summary measure: Difference and Odds -ratio comparing 4-week CFR in the canakinumab 
and control groups.
3 Study  design
This is a multi center , double -blind, randomized, placebo
-controlled study to assess the efficacy 
and safet y of canakinumab plus SOC compared with placebo plus SOC in adult patients (for 
US only : patients ≥ 12 y ears old) with COVID -19-induced pneumonia and CRS (Figure 3 -1).
The study  aims to 
randomize approximately  450 patients worldwide. Enrollment will stop as 
soon as the target number of randomized patient s is reached. Based on the evolving landscape 
in the treatment of COVID- 19, additional arms may  be added to this protocol in the future.
Patients who meet the inclusion/exclusion criteria will be randomized in a 1:1 ratio to either 
canakinumab + SOC or placebo + SOC and can be dosed immediately  after ensuring that the 
patien
t has met all eligibility  criteria .Patients in the canakinumab arm willbe dosed on Day  1 
with canakinumab 450 mg for body  weight of 40-<60 kg, 600 mg for 60-80kg or 750 mg for 
>80kg) in 250 mL of 5% dextrose infused IV over 2 hours .Patients in the placebo arm will be 
treated with 250 mL of 5% de xtrose infused IV over 2 hours.
An informed consent (for US patients 12 - <18 years old; parent/guardian consent must be 
obtained and assent if applicable) will be obtained from patients before assessments solely 
required for the study  are performed. Thereafter, eligibility  criteria will be reviewed by study 
personnel. All patients with signed informed consent must be registered in the Interactive 
Response Technology  (IRT) system .
 Then
additional safety  assessments will be performed approximately every other day during 
hospitalization as described in Table 8-1.Additional follow - up visits will occur on D ays15, 29, 
57and 127either by phone ,if previously  discharged ,or in the hospital ,if still hospitalized . If 
a patient is hospitalized for longer than Day 29, allinvasive protocol assessments will be 
discontinued except at Day s 57 and 127, if still hospitalized. If the patient has been discharged, 
the patient should be phoned for follow -
up and data collected as in Table 8-1. In addition, 
unscheduled visits are permitted after discharge, as needed.
If patient discontinues the study prior to Day 29, then Day 29 assessments should be conducted 
on the day of discontinuation. If patient discontinues the study  after Day 29, then Day 127 
assessments should be conducted on the day  of discontinuation.
Analyses for safety  will be conducted at regular intervals using an internal 
Novartis data 
monitoring committee (DMC ).Deaths and SAEs will be monitored in real time with routine 
pharmaco vigilance and by theinternal, independent DMC in order to detect any unexpected 
safet y signal. The DMC will function independently of all other individuals associated with the 
conduct of this clinical trial.
Patients who do not meet the criteria for parti cipation in this study  (screen failures) will not be 
re-screened.

Novartis Confidential Page 25of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Figure 3-1 Study  design
4 Rationale
4.1 Rationale for study  design
This randomized, double -blind, placebo -controlled design supports the rigorous assessment of 
efficacy  as well as safet y of canakinumab + SOC therap y for patien ts with COVID -19-induced
pneumonia and CRS.
Screening Period
The screening period allows for assessment of patient entry  criteria to ensure 
suitable patients 
are entered into the study , while allowing flexibility  to dose the same day after ensuring 
eligibility  criteria are met.
Study Period
On Day 1, canakinumab (450 mg for body  weight of 40-<60 kg, 600 mg for 60-80 kg or 750 
mg for >80 kg)versus placebo in 250mL of 5% dextrose administered intravenousl y
.The 
blinding will be performed by  an unblinded pharmacist or designated person .
Due to the extended half-life of canakinumab, patients will be followed until Day 127.The 
endpoints included in this study  measure clinical status, clinical and in -hospital outcomes, and 
laboratory values during the Study  Period.
4.2 Rationale for dose/regimen and duration of treatment
The IV delivery  of a single high dose of canakinumab , which is supported by available safet y 
data, ensures a fast decrease in pharmacologically active IL -1β levels and is expected to reduce 
IL-1β signaling to low levels within hours. Adaptation of the dose to body  weight using 3 weight 
ranges /dose levels (450, 600 and 750 mg) minimizes complexity  in the dosing procedure while 
taking the patient ’s weight into consideration. The dose levels were selected based on the 
following considerations and will be added to standard -of-care therap y:

Novartis Confidential Page 26of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
In COV ID-19- induced pneumonia patients, there seems to be a stage at which CRS may 
become a predominant factor in outcomes. The amount of released cy tokines may  be 
estimated to be about 30 -60 fold above baseline values requiring a high dose . Man y 
cytokines have been assay ed and showed increased concentrations.
Registered canakinumab doses in currentl y marketed indications vary  from 2 to 8 mg/kg 
in children and from 150 to 600 mg b y subcutaneous (s.c.) route in adults . The dose sof 10 
mg/kg or 600 mg iv canakinuma b ha
vebeen previously  investigated in 288 patients or 
healthy  volunteers (including children >3 y ears of age) as single or repeated dose sin 
autoinflammatory  conditions, gout y arthritis, asthma, type 2 diabetes mellitus, and ocular 
conditions in the devel opment program. Canakinumab was safe and well tolerated in all 
studies, with no safety  concern identified by  anal ysis of AE, laboratory  or vital signs.
The 450mg for bod y weight of 40 -<60kg, 600 mg for 60
-80 kg and 750 mg for >80kg
dosing regimen was sele cted in order to reach the maximal and safe highest exposure to 
canakinumab of approximately  10 mg/kg. Theintravenous ( IV)route will give higher 
exposure as compared to s.c. shortly  after dosing which is considered critical for treatment 
of CRS especiall y given the rapid decrease in clinical outcomes observed in some patients 
with COVI D-19 pneumonia .
A relativel y high dose is proposed:
To take into account the possibility  of lower drug concentrations in CRS 
patients (asis seen with tocilizumab, Leet al 2018 )
To take into account the unknown diffusion in inflamed lung tissues
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
Currently , no approved treatment for COVID -19induced pneumonia and CRS is available. A 
placebo- controlled study  should mitigate the potential biases associated with the clinical setting 
and the endpoints related to the study  objectives and allow for an objective assessment of 
canakinumab value in this indica tion.
4.4 Purpose and timing of interim analy ses/design adaptations
Not Applicable.
4.5 Risks and benefits
Potential patient benefits
As of March 28, 2020, COVID - 19 has been confirmed in 629,355 people worldwide with 
28,963 deaths reported (Worldometers 2020). As of March 12, 2020, the mortality  rate was 
calculated at approximately  3.7%, compared with a mortalit y rate of less than 1% from 
influenza. Currently , there are no approved treatments nor vaccine s, and so there is an urgent 
need for effective treatment (Mehta et al 2020).
SARS -CoV -
2 is characterized by a spherical morphology  with 36 spike projections on the 
surface and is similar to the β -coronaviruses gene rally seen in bats ( Ahn et al 2019) . The novel 
coronavirus, SARS -CoV -2 uses the same receptor, ACE2 as that for SARS- CoV (cause of 

Novartis Confidential Page 27of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
previous corona virus epidemic), and mainly  spreads through the respiratory  tract. T he clinical 
symptoms of COVID -19 patients include fever, cough, fatigue, loss of smell, and shortness of 
breath within 2-14 days after exposure (CDC 2020). The current SARS -CoV - 2 pandemic is 
resulting in 10-20% of infected patients developing severe illness. The severe clinical course 
includes interstitial pneumonia that can abruptly evolve within a few days to ARDS and multi -
organ failure. Severe infection is also associated with high elevation of acute -phase reacta nts, 
including CRP. This clinical picture of increased cytokines and multi
-organ failure is consistent 
with CRS. Canakinumab is an IL-1β inhibitor which could improve the outcomes of patients 
with COVID -19-induced pneumonia and CRS based on its effect on the inflammasome 
pathway .
Hyper-activated innate immune responses drive tissue injury  during viral infections, and 
increased IL-1β production via 
the NLRP3 inflammasome has been shown to accelerate lung 
pathology  and fibrosis in the context of sterile inflammation or viral infection. Coronaviruses 
can specifically  activate the NLRP3 inflammasome, and by  promoting bronchial epithelial cell 
death, can further exacerbate inflammasome- driven IL-1β production. Bats, which act as an 
asymptomatic reservoir forcoronaviruses, have reduced NLRP3 inflammasome activity , 
linking IL-1β to the organ -specific manifestations seen in humans. Increased levels of IL-1β 
and/or its downstream effector IL-6 have been detected in SARS -CoV and in COVI D-19 
patients and correlate with severit y of clinical symptoms. Neutralization of IL-1β and/or its 
downstream cytokine IL-6 has shown benefit in preclinical models of CRS and in the clinic 
with patients undergoing CAR -T therap y. Furthermore, case studies using the IL-6R 
neutralizing antibody  tocilizumab have shown benefit in treating COVID -19 patients. 
Neutralization of IL-1β upstream of IL-6 could address some of the additional pleiotropic 
tissue -destructive effects of IL-1β in the lung, and canakinumab and other IL-1 antagonists ha ve 
a lower risk of infection than IL -6-target ing agents such as tocilizumab.
Accumulating evidence suggests that patients develop CRS with severe acute pneumonia due 
to COVI D
-19. Currently , there is no clinical experience with canakinumab in the treatment of 
SARS -CoV -2 pneumonia nor cytokine release syndrome per se. However, thecytokine 
profiling of patients with severe COVID -19 which is associated with elevated levels of IL-1, 
IL-2, IL-7, IL-6, granulocy te-colon y stimulating factor, interferon- γ inducible protein 10, 
monocy te chemoattractant protein 1, macrophage inflammatory protein 1 -α and tumor necrosis 
factor -α suggests that canakinumab could improve patient outcomes (Mehta et al 2020, Zhou et 
al 2020
).
Based on these findings, canakinumab may  have a role in reducing the inflammatory  response 
in patients with 
COVI D-19- induced pneumonia and CRS.
Potential risks due to study  medication
The risk to patients in this trial willbe minimized by adherence to the eligibility  criteria and 
close clinical 
monitoring, including by an internal DMC. Over 2,600 patient s including 
approximately  480 children (aged 2 to 17 years) have been treated with canakinumab in 
interventional studies i n Periodic fever syndromes, Still’ s disease, gout y arthritis, or other IL -1 
beta mediated diseases, and healthy  volunteers. The most frequently  reported adverse drug 
reactions were infections, predominantly  of the upper respiratory  tract. The majority  of the 
events were mild to moderate although serious infections were observed. No impact on the type 

Novartis Confidential Page 28of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
or frequency  of adverse drug reactions was seen with longer -term treatment. Hypersensitivity 
reactio ns and opportunistic infections have been reported in patie nts treated with canakinumab. 
Neutropenia and leukopenia has also been observed with IL-1 inhibitors including canakinumab, 
with transient decreases to <1x109/L observed during cl inical trials with canakinumab.
In addition to experience in approved indica tions, over 10,000 patients were enrolled inthe
CANTOS study  evaluating canakinumab for the prevention of recurrent cardiovascular events 
among stable post-myocardial infarction patients with elevated CRP, with a cumulative 
exposure of 32662.6 patient -years (21745.1 patient- years fortotal canakinumab and 10917.5 
patient -years total for placebo).
No clinically  meaningful differences between canakinumab and placebo were observed for 
most safet y topics of interest, apart from an increase in serious infection s and of fatal 
infections/sepsis; however, the overall incidence was low. The pattern of infections was stable 
over time, with very few confirmed opportunistic infections distributed evenl y across the 
treatment groups. There was no evidence of tuberculosis reactivation in canakinumab- treated 
patients.
The overall incidences of investigator -reported infection AEs and discontinuations due to 
infection AEs were comparable across the treatment groups. For investigator -reported infection 
SAEs, there were numeric al differences of 1-2% in the overall incidence for the canakinumab 
300 mg and 150 mg groups compared with placebo. Similarly , a slightly  higher percentage of 
patients discontinued due to an infection SAE in the canakinumab 300 mg and 150 mg groups 
than inthe placebo group. The majorit y of infection AEs consisted of non-serious upper 
respiratory  tract infections which showed no clinically  meaningful differences across the 
treatment groups. Increases in the order of 
1% with canakinumab relative to placebo in the 
overall population were seen for certain infection events, i.e., sepsis, cellulitis, infectious 
pneumonias. The increase in cellulitis was seen predominately  in patients with type-2 diabetes 
mellitus, and that of infectious pneumonias in patients with a history of asthma/ chronic 
obstructive pulmonary disease . There was no meaningful difference between canakinumab 150 
mg and 300 mg in the risk of cellulitis or infectious pneumonias; however, a higher risk of 
sepsis AEs with canakinumab 300 mg was obser ved.
Laboratory  data showed an increase with canakinumab 300 mg only in mild neutrophil and 
platelet count abnormalities (Grade 1), with no imbalances in larger declines (Grades 2-4) in 
neutrophil and platelet counts, or in trigly ceride lev els, between 300 mg and 150 mg.
All
-cause mortalit y was numericall y lower across the three canakinumab treatment groups 
compared to placebo, with both fewer cardiovascular deaths and non-cardiovascular deaths. 
There was an increased incidence of deaths due to infection/sepsis for canakinumab 150 mg vs. 
placebo, although the numbers of related deaths were low overall.
The main adverse drug reaction was infection, of which the most common included viral u pper 
respiratory  tract infection, influenza, and pneumonia.
Overall, the safet y and tolerability  profile of canakinumab in postmyocardial infarction patients 
was consistent with the known safet y profile in the approved indications.
Known risks of canakinu mab pertinent to short term use include the risks of infection (including 
opportunistic infection), interaction with live vaccines and the use in combination with other 

Novartis Confidential Page 29of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
immunosuppressant’s (including TNF inhibitors) due to increas ed risk of serious infecti ons. 
Taking into account the individual risks as outlined above, the expected risk profile of 
canakinumab from its mechanism of action is expected to be similar to that previously  observed. 
Based on overall risk-benefit assessment, the very high unmet medi cal need and the 
implemented controlled setting, the current trial with canakinumab is justified.
There is a limited amount of data from literature and post-marketing reports on the use of 
canakinumab in pregnant women. Animal studies do not indicate direc t or indirect harmful 
effects with respect to reproductive toxicity .The risk for the fetus/mother is unknown. 
Monoclonal antibodies such as canakinumab actively  cross the placenta and are detectable in 
the fetus, predominantly in the second and third trimesters of pregnancy. Based on limited 
human data, canakinumab levels were detected in cord and neonatal blood. The clinical impact 
of this is unknown. However, administration of live vaccines to newborn infants exposed to 
canakinumab in utero is not recomm ended for 16 weeks following the mother's last dose of 
canakinumab before childbirth .
It is not known whether 
canakinumab is transferred intobreast milk. There are no data on the 
effects of canakinumab on the breastfed child or the effects of canakinumab on milk production. 
Animal studies have shown that a murine anti-murine IL-1 beta antibody had no undesirable 
effects on development in nursing mouse pups .
For a comprehensive assessment of the risks of canakinumab, refer to theInvestigator’ s 
Brochure ( IB).
Study specific risks
Protocol -mandated invasive procedures performed during this study  include blood sampling for 
the collection of safet y laboratory  parameters, .
Chest radiograph orCT scan are required for the diagnosis of COVID -19-induced pneumonia 
prior to study  entry and during follow -
up. Radiation exposure occurs during each procedure. 
The radiation received during one x-ray is the same as 1 to 2 weeks of normal radiation received 
in every day life. The radiation received during one CT exam is the same as 2 - 10 years of 
normal radiation received in everyday  life, depending on the body parts included. Some people 
may experience claustrophobia while inside the CT machine.
Oversight committees
An internal DMC will beestablished comprising of an independent (of the study ) group of 
individuals from Novartis who have experience and expertise in the management of patients 
within this disease area, experience in statistical methods, safet y monitoring and in the 
monitoring of randomized clinical trials who will review safet y data provided by the study  team 
at regular intervals, to ensure the safet y of patients enrolled in this new disease area.

Novartis Confidential Page 30of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
5 Study  Population
The study  population includes adult (for US only: patients ≥ 12years old) male and female 
patients who are hospitalized and diagnosed with COVID - 19-induced pneumonia and CRS .
5.1 Inclusion criteria
Participants eligible for inclusion in this study  must meet allof the following criteria:
1.Male or female
2. A dults ≥ 18years old(for US only : patients ≥ 12 y ears old)
3.Body weight ≥ 40 kg
4.Informed consent must be obtained prior to participation in this study . For US patients 12 
- <18 years old; parent/guardian consent must be obtained and assent if applicable.
5. C linically  diagnosed with the SARS -CoV -2 virus by  PCR or by  other approved diagnostic 
methodology within 7 day sprior to randomization .
6.Hospitalized with COVID -
19-induced pneumonia evidenced by  chest x-ray or CT scan
(taken within 5 day s prior to randomization) with pulmonary  infiltrate .
7.SpO 2≤ 93% on room air ,or arterial ox ygen partial pressure (PaO 2)/fraction of inspired 
oxygen (FiO 2) < 300mmHg (1mmHg=0.133kPa) (corrective formulation should be used 
for higher altitude regions (over 1000m)) .
8.
C-reactive protein ≥20 mg/L or ferritin level ≥600 μg/L .
5.2 Exclusion criteria
Participants meeting an y of the following criteria are noteligible for inclusion in this study .
1. H istory  of hypersensitivity  to canakinumab or to biologic drugs .
2.Intubated and on mechanical ventilation (invasive) at time of randomization
3. Treatment with immunomodulators or immunosuppressant drugs, including but not 
limited to tocilizumab, TNF inhibitors and anti -IL-17 agents within 5 half -lives or 30 day s 
(whichever is longer) prior to randomization with the exception of anakinra which is 
excluded within 5 half -lives only . Note: Immunomodulators (topical or inhaled) for 
asthma and atopic dermatitis and corticosteroids (any route of administration) are 
permitted
4.Suspected or known untreated active bacteria l, fungal, viral, or parasitic infection with the 
exception of COVID -
19
5. N eutropenia with ANC <1000/mm3
6.Any serious medical condition or abnormality  of clinical laboratory  tests that, in the 
investigator’s judgment, precludes the patient’s safe participatio n in and completion of the 
study
7. In the opinion of the investigator, progression to death is imminent and highly  likel y 
within the next 24 hours, irrespective of the provision of treatments
8.Current participation in any  other investigational trials

Novartis Confidential Page 31of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
6 Treatmen t
6.1 Stud y treatment
6.1.1 Investigational and control drugs
The study  will enroll patients who require hospitalization and will receive, in addition to the 
local SOC , canakinumab or placebo. The total duration of treatment will be approximately  2 
hours ( Table 6 -1).
Investigational treatment:
Canakinumab dose as per Table 6
-1in 250 mL of 5% dextrose infused IV over 2 hours.
Placebo:
250 mL  of 5% dextrose infused IV over 2 hours
Table 6-1 Canakinumab dose by  body  weight
Patient's weight (kg) Dose of canakinumab Volume of 150 mg/mL
> 80 750 mg 5.0 mL
60 to 80 600 mg 4.0 mL
40 to < 60 450 mg 3.0 mL
Canakinumab or placebo will be prepared by the unblinded pharmacist. Details on the 
requirements for storage and management of study  treatment, and instructions to be followed 
for participant numbering, prescribing/dispensing, and taking study  treatment are outlined in 
the 
Pharmacy  Manual .
6.1.2 Additional study treatments
No other treatment beyond investigational drug and control drug are included in this trial.
6.1.3 Supply  of study treatment
Investigational and control drugs will be provided as described in Table 6 -2.
Table 6
-2 Investigational and control drug
Investigational/ 
Control Drug
(Name and 
Strength)Pharmaceutical 
Dosage FormRoute of
AdministrationSupply Type Sponsor
(global or local)
ACZ885 
150m g/1mlConcentrate for 
solution for 
infusionIntravenous use Open label bulk 
supply; vialsSponsor (global)
Dextrose 5% will be used at thesite to dilute investigational drug or as placebo.

Novartis Confidential Page 32of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
6.1.4 Treatment arms/group
Participants will be assigned at randomization at 1:1 ratio to one of the following treatment 
arms/groups:
Investigational treatment: Canakinumab dose as per Table 6 -1in 250 mL of 5% 
dextrose infused IV over 2 hours.
Reference treatment: 250 mL  of 5% dextrose infused IV over 2 hours.
6.2 Other treatment(s)
6.2.1 Concomitant therapy
All medications, procedures, and signif icant non-drug therapies (including physical therapy  and 
blood transfusions) administered after the participant was enrolled into the study  must be 
recorded on the appropriate Case Report Forms.
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact the Novartis medical monitor before 
randomizing a participant or allowing a new medication to be started. If the participant is 
alread y enrolled, contact Novartis to determine if the participant should continue participation 
in the study .
The patient must be told to notify  the Treating Physician about any new medications that he/she 
takes after the start of canakinumab.
6.2.1.1 Permitted concomitant therapy  requiring caution a nd/or action
Patients in this study  will be enrolled to canakinumab or placebo, in addition to SOC per local 
practice, which may  include anti -viral treatment, corticosteroids and supportive care.
Immunomodulator (topical or inhaled) use for asthma and atopic dermatitis or corticosteroid 
use (per medical judgement) are not restricted.
Use of oral, injected or implanted hormonal methods of contraception are allowed while on 
canakinumab.
6.2.2 Prohibited medication
Thefollow ing medications are prohibited:
Up to Day 29, c oncomitant use of biologics including anakinra, t ocilizumab, abatacept, 
rilonacept, rituximab and any  other biologics (investigational or marketed) and TNF 
inhibitors including etanercept, adalimumab, infliximab and/or other TNF inhibitor s
(investiga tional or marketed).
All investigational medications being used in an investigational trial.
Foradditional infor mation, please refer to the IB.

Novartis Confidential Page 33of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
6.3 Participant numbering, treatment assignment, randomization
6.3.1 Participant numbering
Each participant is identified in the study  by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening and is retained for the participant 
throughout his/her participation in the trial. The Participant No. consists of the Center Number 
(Center No.) (as assigned by Novartis to the investigative site) with a sequential participant 
number suffixed to it, so that each participant’s participation is numbered uniquely  across the 
entire database. Upon signing the informed consent (ICF) form, the participant is assigned to 
the next sequential Participant No. available.
6.3.2 Treatment assignment, randomization
At Randomiza tion visit, all eligible patient s will be randomized via I RT to one of the treatment 
arms. A designated site staff member (preferabl y the pharmacist conducting the blinding) other 
than the investigator or study  staff involved in safet y and efficacy  assessments or eCRF 
completion will contact the IRT after confirming that the patient fulfills all the 
inclusion/exclusion criteria. The IRT will assign a randomization number to the participant, 
which will be used to link the participant to a treatment arm.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from participants and investigator staff. A 
participant randomization list will be produced by the IRT provider, or by a delegate under 
Novartis supervision, using a validated system that automates the random assignment of 
participant numbers to randomizatio n numbers. These randomization numbers are linked to the 
different treatment arms.
If a patient discontinues before Randomization, the I RT should be notified within twodays and 
the reason for not being randomized should be recorded on the app ropriate Case Report Forms.
Randomization will be stratified bycountry toensure a balanced allocation of patient s to 
treatment groups within the strata.
The randomization scheme for participants will be reviewed and approved by  a member of the 
Randomization Office.
6.4 Treatment blinding
This is a double -blind randomized treatment trial. Participants, all site staff (including study 
investigator and study  nurse), persons performing the assessments, andclinical trial team will
remain blind to the identity of the treatmen t from the time of randomization until database lock
for primary  anal ysis.
Unblinding a single participant at site for safet y reasons (necessary  for participant management) 
will occur via an emergency  system in place at the site.
Drug product will be supplied in bulk, so an unblinded pharmacist who is independent of the 
study  team will be required in order to maintain the blind. This unblinded pharmacist will 
receive the treatment arm assigned by the IRT system during the randomization transaction . 

Novartis Confidential Page 35of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
information and confirm the necessity  to break the treatment code for the participant. The 
investigator will then receive details of the investigational drug treatment for the specified 
participant and a fax or email confirming this information. The system will automati cally  
inform the Novartis monitor for the site and the study  team that the code has been broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The investigator 
will provide:
protocol number
participant number
In addition, oral and written information to the participant must be provided on how to contact 
his/her backup in cases of emergency, or when he/she is unavailable, to ensure that un- blinding 
can be performed at an y time.
6.7 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under investigational 
and control drugs section.
Study  drug will be packe d and labeled as ACZ885 and supplied as open label bulk supplies.
Each box will contain multiple vials of ACZ885 150mg/1ml. The box can be used for treatment 
of multiple patients. However, each vial intended for one patient should not be used for another 
patient .
Preparation of the investigational drug must be done in a separa te space/room where study  
personnel have no access during time of preparation
.
6.7.1 Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y and kept in a secured location to which only thedesignated site personnel 
have access. Upon receipt, all study  treatment must be stored according to the instructions 
specified in the IB.
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints 
are to be reported to the respective Novartis Quality Assurance.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include sto rage conditions for the study  treatment but no information about 
the participant except for the medication number .
The pharmacist or other qualified site personnel must maintain an accurate record of the 
shipment and dispensing of study  treatment in a drug accountability  log which will be kept in a 
Pharmacy  File in a secured location to which no blinded s ite staff would have access to.
Study  treatment will be prepared by an independent pharmacist or qualified site personnel in 
order to ensure treatment blin ding as described in Section 6.1.
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused study  treatment, packaging, drug labels, and a copy ofthe completed drug 

Novartis Confidential Page 37of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
8 Visit schedule and a ssessments
The Assessment Schedule (Table 8 -1)lists all of the assessments when they are performed. All 
data obtained from these assessments must be supported in the participant’s source 
documentation.
Participants should be seen or phoned for all visits/assessments as outlined in the assessment 
schedule (Table 8-1)or as close to the designated day/time as possible. Missed or rescheduled 
visits should not lead to automatic discontinuation. At the day of discharge from the hospital, 
all assessments should be conducted per Table 8-1. In addition, contact information for the 
patient and/or legal represent atives should be obta ined for the follow -up visits.
Screening assessments are to be taken as indicated in Table 8 -
1prior to randomization and are 
considered baseline measurements. Patients who meet the inclusion/exclusion criteria may be 
dosed immediately  after obtaining the baseline measurements.

Novartis Confidential Page 38of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Table 8-1 Assessment and Procedures Schedule ( Baseline to 18-week safety  follo w up )13
Visit Day-1 (0-24 hrs 
prior to 
randomization )11 2Every  day during 
hospitalization until 
Day 29 or discharge 
(whichever is earlier) 15229or Day  of 
Discharge2Day 572
(±7 day s)1272
(±7 day s)/ 
End of Study
Informed consent (including optional genetic 
ICFand assent if applicable )3 x
Inclu sion/Exclusion criteria x x4
Demographics / medical history x
SARS -CoV-2 virus testing (local labs) x8Record all testing, if obtained
SARS -CoV-2 nasopharyngeal samples 
(central lab)x x
Vital signs :
Heart rate , Respiratory rate , Oxygen 
saturation orPaO 2/FiO 2, Systolic /diastolic 
blood pressure , Body temperature5x x4x x x x
Height, weight x
Physical exam6S4S S S S
Clinical status evaluation with 9-point ordinal 
scale (e.g. oxygen requirement, 
invasive/non -invasive mechanical 
ventilation, additional organ support)x4x x x x x x
Hematology (local labs)x xx (every other day e.g., 
Days 3, 5, 7, etc.)x x x
Clinical chemistry, CRP, ferritin, d -dimer
(local labs)x xx (every other day e.g., 
Days 3, 5, 7, etc.)x x x
Pregnancy test7(local labs) s s s s
Chest x -rayor CT scan8x Record all pulmonary imaging ifobtained
ECG (local) s s s
Adverse events x x4x x x x x x
Prior/concomitant medications /non-drug 
therapy (i.e. oxygen)x x4x x x x x x

Novartis Confidential Page 41of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
8.1 Screening
No rescreening will be permitted.
8.1.1 Information to be collected on screening failures
Participants who sign an informed consent form and subsequentl y found to be ineligible prior 
to randomization will be considered a screen failure. The reason for screen failure should be 
recorded on the appropriate CRF . The demographic information, informe d consent, and 
Inclusion/Exclusion pages must also be completed for screen failure participants. No other data 
will be entered into the clinical database for participants who are screen failures, unless the 
participant experienced a serious adverse event during the screening phase (see SAE section for 
reporting details). If the 
participant fails to be randomized, the IRT must be notified within 2 
days of the screen fail that the participant was not randomized.
Participants who are randomized and fail to start treatment, e.g. participants randomized in error, 
will be considered an early  terminator. The reason for earl y termination should be recorded on 
the appropriate CRF .
8.2 Participant demographics/other baseline characteristics
Country -specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with CRF .
Participant race and ethnicity  are collected and analyzed to identify  variations in safet y or 
efficacy  due to these factors as well as to assess the diversit y of the study  population as required 
by Health Authorities .
8.2.1 Demographic /baseline characteristics information
Demographic data to be collected at screening on all participants include: year of birth or age, 
gender, race, ethnicity  and child -bearing potential (for females onl y).
Any relevant medical history  including date of onset of COVID -19 disease sy mptoms, date of 
diagnosis of COVID -19 disease protocol solicited medical history , and/or current medical 
conditions before obtaining informed consent will be recorded in the Medical History  CRF. 
Significant findings that are observed after the participant has provided informed consent and 
that meet the definition of an AE must also be recorded in the AE CRF. Whenever possible, 
diagnoses and not s ymptoms w ill be recorded.
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
8.2.2 Prior and concomitant medications
Relevant prior and concomitant medications will be captured at the screening visit, and updated 
at the baseline visit. Any changes to the ongoing medications or any new concomitant 
medications will be recorded in CRF on an ongoing basis throughout stud y participa tion.

Novartis Confidential Page 42of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
8.3 Efficacy
8.3.1 Clinical status ( 9-point ordinal scale)
Assessment of clinical status using a 9-point ordinal scale (WHO 2020b) will be recorded at 
baseline on Day 1 before the start of the study  treatment and then again once per daythrough 
Day 29 of the Study  Period ,if hospitalized (Appendix 1).If a patient is discharged from the 
hospital, the assessment will be made b y phone on the visit dates noted in 
Table 8 -1.Each day , 
the patient’s status from theprevious calendar dayis reviewed; the ordinal score isassigned 
based on thepatient’s worst status from the previous day. This score (based on 
the review of the 
previous day) will be recorded (i.e. on Day  3, the Day  2 score is determined from review of the 
previous day’s data, and the worst score is recorded as the score for Day 2).In addition, on Day 
29 or the Day of discharge, clinical status on Day 29 or the Day of discharge should be recorded.
Table 8-2 Clinical status (9 -point ordinal scale)
Patient StateDescriptorScor
e
UninfectedNo Clinical or 
virological evidence of 
infection 0
Ambulator y (not in hospital or in hospital and ready for 
discharge)No limitation of 
activities 1
Limitation of activities 2
Hospitalized
Mild diseaseHospitalized, no ox ygen 
therapy (defined as 
SpO 2 ≥ 94% on room 
air) 3
Oxygen by mask or
nasal prongs 4
Hospitalized
Severe diseaseNon-invasive ventilation 
or high -flow ox ygen 5
Intubation and 
mechanical ventilation 6
Ventilation + additional 
organ support -
pressors, RRT (renal 
replacement therapy ), 
ECMO (extracorporeal 
memb rane 
oxygenation) 7
Dead Death 8
8.3.2 Vital signs and oxy gen saturation and use
Vital sign measurement sinclude respiratory  rate, pulse rate, systolic and diastolic blood 
pressure, and body  temperature. Vitals signs should be recorded at a consistent time once each 
day for a patient (i.e. morning, afternoon or evening) and upon significant clinical changes .

Novartis Confidential Page 44of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
8.4.1 Laboratory  evaluations
Clinically  significant abnormalities must be recorded as either medical history /current medical 
conditions or adverse events as appropriate.
8.4.1.1 SARS-CoV-2 virus testing
For the Screening inclusion criterion, SARS -CoV -
2 virus should be measured by PCR or by 
other approved diagnostic methodology  ≤ 7days prior to randomization by local lab .
Documentation of the method used should be available in the source notes.
If additional testing is conducted locall y, results should be recorded in the CRF.
8.4.1.2 Laboratory  evaluations
Laboratory  evaluations will be performed by  the local lab.
Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, and 
platelet count will be measured according to the assessment schedule in Table 8 -1.
Chemistry
BUN/urea, creatinine, total 
bilirubin, direct bilirubin, aspartate aminotransferase ( AST ), alanine 
aminotransferase (ALT), alkaline phosphatase, gamma -glutamy l transpeptidase, lactate 
dehy drogenase, sodium, potassium, chloride, calcium, bicarbonate, phosphorus, total protein, 
albumin, glucose, uric acid will be measured according to the assessment schedule in Table 8 -
1. If a given test is not available locall y, this should be documented on the eCRF.
Additional markers of inflammation: CRP, ferritin, and d-dimer should be collected in 
accordance with Table 8
-1.
In the case where a labora tory range is not specified by  the protocol, but a value is outside the 
reference range for the laboratory  at screening and/or initial baseline, a decision regarding 
whether the result is of clinical significance or not shall be made by the Investigator (in 
consultation with the sponsor) and shall be based, in part, upon the nature and degree of the 
observed abnormalit y. In all cases, the Investigator must document in the source documents, 
the clinical considerations (i.e., result was/was not clinically  significant and/or medically 
relevant) in allowing or disallowing the participant to continue in the study .
All patients with laboratory  tests containing clinically  significant abnormalities should be 
followed until the values return to within the normal ranges or until a clinical explanation is 
identified, even after study  medication has discontinued.
8.4.2 Physical exam
A complete physical examination will be performed for baseline measurement at the time point 
defined in Table 8-1.It will include the examination of general appearance, skin, neck 
(including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 

Novartis Confidential Page 45of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
extremities, vascular and neurological. Then, for remaining time points , targeted physical 
examination, per investigator discretion, may  be performed.
Information for all phy sical examinations must be included in the source documentation at the 
study  site. Significant findings that are present prior to informed consent being gr anted must be 
included inthe Relevant Medical History /Current Medical Conditions screen on the patient’s 
eCRF. Significant findings made after informed consent is given which meet the definition of 
an Adverse Event must be recorded on the Adverse Event sc reen of the patient’s eCRF.
8.4.3 Height, weight
Height in centimeters will be measured at the Screening visit as specified in the table of 
assessments ( Table 8 -1).
Body weight (to the nearest 0.1 kilogram in indoor clothing, but without shoes) will be 
measured at the Screening visit as specified i n the table of assessments ( Table 8 -
1).
8.4.4 Electrocardiogram (ECG)
An ECG will be taken locally  as specified in the Table 8
-1
The ECG should be recorded after 10 minutes of rest in the supine positi on to ensure a stable 
baseline.
Each ECG tracing should be labeled with study  number, patient initials patient number, date 
and time, and filed in the study  site source documents.
Clinically  significant abnormalities should be recorded on the relevant section of the medical 
history /Current medical conditions/AE CRF /eCRF page as appropriate. If necessary , a 
cardiologist may  be consulted.
8.4.5 Pregnancy  and assessments of fertility
All women of child- bearing potential (except if alread y confirmed pregnant) will have a serum 
pregnancy  test at Screening and urine or serum pregnancy  test at subsequent designated visits 
(Table 8 -1), if hospitalized .Pregnancy  tests will be conducted at the local lab and documented 
in the source documents.
8.4.6 Chest x -ray or CT scan
Standard chest x
-ray or CT scan will be performed for eligibility  except for those who have had 
a valid x -ray or CT scan done within 5 days prior to randomization. The results must be known 
prior to random ization to determine the patient’s eligibility  for the study . Additional chest x-
rays (or CT scan) will be perform ed, as needed .
Chest x -ray or CT scan results will be recorded in the CRF.
8.4.7 Appropriateness of safety  measurements
The safet yassessments selected are appropriate for this protocol which utilizes a marketed 
compound where the safety  profile has been established. The assessments are relevant to the 
critical care setting and will enable determination of therapeutic response in thi s setting.

Novartis Confidential Page 46of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
8.5 Additional assessments
8.5.1 SARS-CoV-2 nasophary ngeal samples
Viral load may be measured by assessment of nasophary ngeal swabs sent to the central lab at 
time points designated in the assessment schedule (Table 8-1). Nasopharyngeal swabs should 
be taken in both nostrils orin the same nostril throughout the trial (whenever possible).
Laboratory  Manuals will be provided with detailed information on sample collection, handling, 
and shipment

Novartis Confidential Page 47of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
9 Study  discontinuation and completion
9.1 Discontinuation and completion
9.1.1 Study treatment discontinuation and study discontinuation
Discontinuation of study  treatme nt for a participant occurs when study  treatment is stopped 
earlier than the protocol planned duration and can be initiated by either the participant or the 
investigator.
The investigator must discontinue study  treatment for a given participant if, he/she believes that 
continuation would negatively  impact the participant's well- being.
Study  treatment must be discontinued un der the following circumstances
Participant/guardian decision
Use of prohibited treatment as per recommendations in the prohibited treat ment section
Any situation in which study  participation might result in a safet y risk to the participant
Following emergency  unblinding

Novartis Confidential Page 48of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Emergence of adverse events that in the judgment of the investigator, taking into account 
the participant’s overall status, prevent the participant from contin uing participation in the 
study
Any laboratory  abnormalities that in the judgment of the investigator, taking into 
consideration the participant’s overall status, prevents the participant from continuing 
participation in the study
Severe h ypersensitivity  reaction occurs, including any  of the following: anaphy laxis, 
fever, chills, urticaria, d yspnea, headache, myalgia, hy potension. Immediate interruption 
of the infusion to administer study  treatment is required in such cases.
If discontinuation of study  treatment occurs, the investigator should make a reasonable effort 
to understand the primary  reason for the participant’s premature discontinuation of study 
treatment and record this information.
Participants who discontinue study  treatment or who decide they do not wish to participate in 
the study  further should NOT be considered withdrawn from the study  UNLESS they withdraw 
their consent (see 'Withdrawal of Informed Consent' section). Where possible, they should 
return for the assessments indicated in the Assessment Schedule. If they fail to return for 
these assessments for unknown reasons, every  effort (e.g. telephone, e-mail, letter) should be 
made to contact the participant/pre -designated contact as specified in the lost to follow -up 
section. This contact should preferabl y be done according to the stud y visit schedule.
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain 
regular telephone contact with the participant, or with a person pre-designated by the participant. 
This telephone contact should preferabl y be done according to the stud y visit schedule.
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected a t clinic visits or via telephone/email contact:
New / concomitant treatments
Adverse Events / Serious Adverse Events
The investigator must also contact the IRT to register the participant’s discontinuation from 
study  treatment.
If disconti nuation occurs because treatment code has been broken, please refer to Emergency 
breaking of treatment code section.
9.1.2 Withdrawal of informed consent
Participants may  voluntarily  withdraw consent to participate in the study  for any  reason at any  
time. Withdrawal of consent (WoC) occurs onl y when a participant:
Does not want to participate in the study  anymore,
and
Does not want an y further visits or assessments
and
Does not want an y further study related contacts

Novartis Confidential Page 49of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the participant’s decision to withdraw his/her consent and 
record this information.
Where consent to the use of personal and coded data is not required, participant therefore cann ot 
withdraw consent. They  still retain the right to object to the further use of personal data.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered m issing.
Further attempts to contact the participant are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  discontinuation. A final 
evaluation at the time of the participant’s study  discontinuation should be made as detailed in 
the assessment table.
Novartis will continue to retain and use all research results (data) that have alread y been 
collected for the study  evaluation.
9.1.3 Lost to follow -up
For participants whose status is unclear because they fail to appear for study  visits without 
stating an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the participant, e.g. dates of 
telephone calls, registered letters, etc. A participant should not be considered as lost to follow -
up until due diligence has been completed or until the time point of his/her scheduled last stud y 
visit has passed.
9.1.4 Early  study termination by  the sponsor
The study  can be terminated by  Novartis at any  time.
Reasons for earl y termination:
Unexpected, significant, or unacceptable safet y risk to participants enrolled in the study
Decision based on recommendations from the internal data monitoring committee (DMC) after 
review of safet y and efficacy  data
In taking the decision to terminate, Novartis will alway s consider participant welfare and safet y. 
Should early  termination be necessary , participants must be seen as soon as possible and treated 
as a prematurel y withdrawn participant. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the 
protection of the participant’s interests. The investigator or sponsor depending on local 
regulation will be responsible for informing IRBs/IECs of the early  termination of the trial.
9.2 Stud y completion and post -study  treatment
Study  completion is defined as when the last participant finishes their Study  Completion visit 
and any repeat assessments associat ed with this visit have been documented and followed- up 
appropriatel y by the Investigator or, in the event of an early  study termination decisi on, the date 
of that decision.

Novartis Confidential Page 50of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Continuing care should be provided by the investigator and/or referring physician based on 
participant a vailabilit y for follow -up.
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event isany untoward medical occurrence (e.g. any unfavorable and unintended 
sign [including abnormal laboratory  findings], symptom or disease) in a clinical investigation 
participant after providing written informed consent for participation in the study . Therefore, 
an AE may or may not be temporally  or causally  associated with the use of a medi cinal 
(investigational) product.
The investigator has the responsibility  for managing the safety  of individual participant and 
identify ing adverse events.
Novartis qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by non-directive questioning of the participant 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by the participant during or between visits or 
through physical examination findings, laboratory  
test findings, or other assessments .
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, 
accompanied by thefollowing information (as far as possible) (if the event is serious refer to 
Section 10.1.2):
1.
Severity  grade:
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with nor mal activities
severe: prevents normal activities
2.Its relationship to the study  treatment .If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study  indication) the assessment of causalit y 
will usually  be ‘Not suspected.’ The rationale for this guidance is that the sy mptoms of a 
lack of efficacy or progression of underly ing illness are not caused by  the trial drug, they  
happen in spite of its administration and/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by an anal ysis of cohorts, not on a 
single participant
3.Its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported
4.Whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5.Action taken regarding with study  treatment.

Novartis Confidential Page 51of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
All adverse events must be treated appropriatel y. Treatment may include one or more of the 
following:
Dose not changed
Dose Reduced/increased
Drug interrupted/w ithdrawn
6.Its outcome (i.e. recovery  status or whether it was fatal)
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history of the participant.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued to the end of stud y visit.
Once an adverse event is detected, it must be followed until its reso lution or until it is judged to 
be permanent (e.g. continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently , if necessary ) of an y changes in severity, the suspected relationship to 
the interventions required to tre at it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator's Brochure (IB).
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typical in participant 
with the underly ingdisease.
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearanc e of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
consti tutes a congenital anomaly /birth defect

Novartis Confidential Page 52of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
requires in- patient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for:
routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respite care in the absence of any  deterioration in the participant’s 
general condition
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
is medically  significant, e.g. defined as an event that jeopardizes the participant or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately  
life threatening or result in death or hospitalization but might jeopardize the participant or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant.” Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospitalization or development of dependency  or abuse (please refer to the ICH-
E2D Guidelines).
All new malignant neoplasms will be assessed as serious under “medicall y significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports ofintentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred. SAE reporting
10.1.3 SAE reporting
To ensure participant safety , every  SAE, regardless of causalit y, occurring after the participant 
has provided informed consent and until the last study visit must be reported to Novartis safet y 
within 24 hours of learning of its occurrence. Detailed instructions regarding the submission 
process and requirements are to be found in the investigator folder provided to each site.
Screen Failures (e.g. a participant who is screened but is not treated or randomized): SAEs 
occurring after the participant has provided informed consent until the time the participant is 
deemed a Screen Failure must be reported to Novartis.
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.

Novartis Confidential Page 53of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
If the SAE is not pr eviously  documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, an associate from the Chief 
Medical Office and Patient Safety (CMO &PS) Department may urgently  require further 
inform ation from the investigator for health authority  reporting. Novartis may  need to issue an 
IN to inform all investigators involved in any study with the same study  treatment that this SAE 
has been reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
Any SAEs experienced after the last study  visit should only be reported to Novartis Safet y if 
the investigator suspects a causal relationship to study  treatment.
10.1.4 Pregnancy  reporting
If a female trial participant becomes pregnant, or is enrolled while pregnant, the trial participant 
must be asked toread and sign pregnancy  consent form to allow the Study  Doctor ask about her 
pregnancy . To ensure participant safet y, if a pregnant patient is enrolled or a patient becomes 
pregnant after signing the informed consent , this must be reported to Novartis within 24 hours 
of learning of its occurrence. The pregnancy  should be followed up to determine outcome, 
including spontaneous or voluntary  termination, details of the birth, and the presence or absence 
of an y birth defects, congenital abnormalities, or ma ternal and/or newborn complications.
Pregnancy  should be recorded and reported by the investigator to CMO&PS. Pregnancy  follow -
up should be recorded on the same form and should include an assessment of the possible 
relationship to the study  treatment any pregnancy  outcome. Any SAE experienced during 
pregnancy  must be reported.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, 
administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persis tent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  harmful ph ysical or psy chological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irres pective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being associated with an AE/SAE within 24 hours of 
Investiga tor’s awareness.

Novartis Confidential Page 54of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dosing 
CRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
10.2 Additional Safety  Monitoring
10.2.1 Liver safety monitoring
To ensure participant safety and enhance reliability  in determining the hepatotoxic potential of 
an investigation al drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
Please refer to Table 16-1 in Appendix 3 for complete definitions of liver laboratory triggers.
Once a participant is exposed to study  treatment, every  liver event defined in Table 16-1 should 
be followed up by the investigator or designated personnel at the trial site, as summarized below. 
Additional details on actions required in case of liver events 
are outlined in Table 16 -2. Repeat 
liver chemistry  tests (i.e. AL T, AST, TBL, PT/INR, AL P and GGT) to confirm elevation.
These liver chem istry repeats should be performed using the local laboratory  used by  the 
site. Repeated laboratory  test results must be reported as appropriate.
If the initial elevation is confirmed, close observation of the participant will be initiated, 
including consid eration of treatment interruption if deemed appropriate.
Hospitalization of the participant if appropriate
Causality  assessment of the liver event
Thorough follow -
up of the liver event should include
Based on investigator’s discretion: serology  tests, imag ing and pathology  
assessments, hepatologist’s consultancy ; obtaining more detailed history  of sy mptoms 
and prior or concurrent diseases, history  of concomitant drug use, exclusion of 
underly ing liver disease
All follow -up information and procedures perform ed must be recorded as appropriate in the 
CRF.
10.2.2 Data Monitoring Committee
This study  will include an internal data monitoring committee (DMC) which will function 
independentl y of all other individuals associated with the conduct of this clinical trial, including 
the site investigators participating in the study . The DMC will assess at defined intervals the 
progress of a clinical trial, safet y data, and critical efficacy  variables and recommend to the 
sponsor whether to continue, modify , or terminate a trial.

Novartis Confidential Page 55of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Specific details regarding composition, responsibilities, data monitoring, and meeting 
frequency , and documentation of DMC reports, minutes, and recommendations will be 
described in a separate charter that is established with the DMC.
11 Data Collection and Database management
11.1 Data collection
All data should be recorded, handled, and stored in a way that allows its accurate reporting, 
interpretation, and verification.
Designated investigator staff will enter the data required by the protocol and defined in the 
Assessment Schedule (Table 8-1) into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully  validated secure web-
enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they 
have been trained. Automatic validation programs check for data discrepancies in the eCRFs, 
allow modification and/or verification of the entered data b y the investigator staff.
The investigator/designee is responsible for assuring that the data (recorded on eCRFs) (entered 
into eCRF) is complete, accurate, and that entry and updates are performed in a timely  manner. 
The Investigator must certify  that the data entered are complete and accurate.
After final database lock, the investigator will receive copies of the participant data for 
archiving at the investigational site.
11.2 Database management and quality  control
Novartis personnel (or designated CRO) will review the data entered byinvestigational staff 
for completeness and accuracy . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Desig nated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employ s the Anatomical 
Therapeutic Chemical classification system. Medical history /current medical conditions and 
adverse events will be coded using the Medical Dictionary  for Regulatory  Activities (MedDRA) 
terminology .
Dates of screenin gs, randomizations, screen failures and study  completion, as well as 
randomization codes will be tracked using an Interactive Response Technology  (IRT). The 
system will be supplied by  the Novartis I RT, who will also manage the database. The data will 
be se nt electronicall y to Novartis) at specific timelines.
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The 
code break functionality  will remain available until study  shut down or upon request of Novartis
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatment codes will be unblinded and made 
available for data anal ysis/moved to restricted area to be accessed by independent programmer 

Novartis Confidential Page 56of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
and statistician. Any changes to the database after that time can only be made after written 
agreement by  Novartis development management.
11.3 Site monitoring
Before study  initiation, at an initiation visit or at an investigator’s meeting, a Novart is 
representative will review the protocol and data capture requirements with the investigators and 
their staff. During the study , Novartis employ s several methods of ensuring protocol and GCP 
compliance and the quality /integrit y of the sites’ data. The field monitor will check the 
completeness of participant records, the accuracy  of data capture / data entry , the adherence to 
the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study  
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor in conducting these activities. Continuous 
monitoring of each site’s data will be performed throughout the conduct of the study .
Additionall y, a central analy tics organization may analyze data & identify  risks & trends for 
site operational parameters, and provide reports to Novartis clinical teams to assist with trial 
oversight.
The investigator must maintain source documents for each participant in the study , consisting 
of case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to the respective source 
documents .The investigator must also keep the original informed 
consent form signed by the 
participant and/or legal representative (a signed cop y is given to the participant).
The investigator must give the monitor acc ess to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Source data verification may be done on-
site, if possible, or remotely, if the field monitor does not have access or have limited access to 
the site due to the current COVID -19 pandemic. Different approaches can be used depending 
on site medical records, and some of them could include sharing the information 
through 
electronic systems or platforms provided by a third party. In all cases ,investigator and sponsor 
must adhere to the recommendations established by the applicable Health Authorities.
Novartis monitoring standards require verification for the presence of all informed consents, 
adherence to the inclusion/exclusion criteria, docu mentation of SAEs, and of data that will be 
used for all primary  variables. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific monitoring plan. No information in source 
documents about the id entity  of the participants will be disclosed.
12 Data analy sis and statistical methods
The primary  analysis of the study  will be performed after all patients finished day 29 assessment 
or discontinued early from study  before Day 29. The final analysis will happen after all patients 
complete the study .
Safety  summaries will be produced for regular DMC safety  monitoring according to the 
schedule of DMC meeting s.

Novartis Confidential Page 57of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Unless if otherwise clarified, descriptive summaries for categorical data will include 
frequencies and percentages, and continuous data will be presented with mean, standard 
deviation, median, minimum, and maximum. For selected parameters, 25th and 75th percentiles 
may also be presented.
Differences , relative risks (RR) andodds ratios (OR) for the compar isons between the two 
treatment arms will be presented with 2-sided 95% confidence interval (CI). P -values will be 
presented if formal h ypothesis test is performed.
Any data analy sis carried out independently  by the investigator should be submitted to Novartis 
before publication or presentation.
12.1 Analysis sets
The Full Anal ysis Set (FAS) comprises all participant to whom study  treatment has been 
assigned b y randomization. According to the intent to treat (ITT) principle, participants will be 
analyzed according to the treatment they have been assigned to during the randomization 
procedure. Efficacy  analy seswill be performed on the FAS.
The Safet y Set includes all participants who received at least one dose of study  treatment. 
Participants will be analy zed according to the study  treatment received , where treatment 
received is defined as the randomized/assigned treatment if the participant took at least one dose 
of that treatment or the first treatment received if the randomized/assigned treatment was never 
received. The Safet y Set will be used in the anal ysis of all safet y variables.
12.2 Participant demographics and other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed and 
summarized descriptively by treatment group for the FAS. Detailed list of demographic and 
baseline characteristic parameters will be included in SAP .
12.3 Treatments
Analy ses on treatment and exposure will be on safety  set.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical 
Therapeutic 
Chemical (ATC) classification sy stem, by  treatment group.
12.4 Analysis of the primary  endpoint(s)/estimand(s)
The primary  analysis for this study will be conducted on the FAS using treatment policy  strategy .
12.4.1 Definition of primary  endpoint(s)/estimand(s)
The primary  estimand, including primary endpoints, are defined in Section 2.1 of this protocol. 
The primary  endpoint will be derived based on the 9-point ordinal scale of clinical status
(Appendix 1 ).
Additional details on primary  endpoint derivation will be included in SAP.

Novartis Confidential Page 59of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
12.5 Analysis of secondary  endpoints/estimands
12.5.1 Key secondary  endpoint
Thekey secondary  endpoint is theCOVID -19 related death during the 4-week period after study 
treatment. Hypothesis test for the key secondary  analysiswill be performed if and only if the 
null hy pothesis for the primary  anal ysis is rejected.
The null hy pothesis for the key  secondary  anal ysis is that there is no 
difference in the COVID -
19 related death rate (i.e. CFR )in patients treated with canakinumab compared to patients on 
placebo. The test of the hypothesis will be based on a logistic regression model adjusted for 
treatment, region and the baseline clinical status. The null hypothesis will be rejected if the 
observed p-value for treatment comparison (based on the CFR ratio) is less than the significance 
level of 0.05. Model -based estimates of the CFRand their 95% confidence intervals (CIs), 
estimate of the CFR ratio and 95% CI, and p-value for comparing canakinumab vs . placebo will 
be provided.
The number and percent of patients with COVID -19 related death during the 4-week period 
will also be provided b y treatment arms.
The key secon dary efficacy  analysis 
is based on FAS. Patients who are lost to follow -up or 
discontinue early from study  before Day 29 will be deemed as survivor if the latest clinical 
status is 0 or 1 on the 9-point ordinal scale. Otherwise, the patient will not be included in the 
analysis.
A sensitivity  analysis will be provided by considering all patients who lost to follow -
up or 
discontinue earl y from study before Day  29 as survivors.
12.5.2 Other Secondary  objectives and endpoints
Descriptive statistics (mean, standard deviation, median, minimum and maximum) will be 
provided for variables that are of the numeric or continuous type, while frequency distributions 
(with number and percent ) will be provided for variables that of the categorical ty pe.
12.5.3 Safety  endpoints
All safety analyses will be based on the safet y set including all data collected on or after the 
first dose date .
Adverse events
The number (and percentage) of patients with treatment emergent adverse events (events started 
after the first dose of study medicatio n or events present prior to start of double -blind treatment 
but increased in severit y based on preferred term) will be su mmarized in the following way s:
by treatment, primary  system organ class and preferred term.
by treatment, primary  system organ class, preferred term and maximum severity .
by treatment, Standardized MedDRA Query  (SMQ) and preferred term.
A participant with multiple adverse events within a primary s ystem organ class is only counted 
once towards the total of the primary  system organ class.

Novartis Confidential Page 60of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Similar summaries will be provided for stud y medication related adverse events, death, serious 
adverse events.
The number (and proportion) of participants with adverse events of special interest/related to 
identified and potential risks (i.e.Infections, Opportunistic infections, Drug induced liver injury , 
Immunosuppressants combination therapy  toxicity , Interactions with vaccines, Macrophage 
activation sy ndrome ) will be summarized by  treatment.
Deaths, serious AEs, and study  medication related AEs will be listed separately .
Vital signs
Vital signs data will be summarized by treatment and visit.
Clinical laboratory  evaluations
Laboratory  data will be summarized by treatment and visit.
12.5.4 Biomarkers
Adjusted geometric mean ratio to baseline in serum ferritin, CRP and D-dimer will be reported
by treatment arm and visit.

Novartis Confidential Page 61of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
12.6 Interim analy ses
Summaries of safet y data willbe produced for DMC safety  mon itoring when needed.
12.7 Sample size calculation
12.7.1 Primary  endpoint(s)
Approximately  450 patients will be randomized to canakinumab + SOC or placebo + SOC in a 
1:1 ratio.
Patients infected with COVID -19 exhibit a wide range of clinical severit y. With recent initial 
outbreak and evolving pandemic situations, limited data is available to precisel y estimate the 
rate of disease progression after hospital 
admission for the population of interest under SOC. 
The CDC reported 31.4% hospitalizations and 11.5% ICU admissions (among patients with 
known hospitalization and IC U admission status) in the United States between February  12 and 
March 16, 2020 ( CDC COVID Response Team 2020 ). An earlier summary (Wu and McGoogan 
2020) of 72314 diagnosed cases in China estimated about 81% mild cases, 14% severe cases, 
5% critical case and an overall case-fatality rate of 2.3%. A worldwide tally by WHO as 
of 
March 12th, 2020 estimated a mortality rate of 3.7% with 125,048 confirmed cases. A study b y 
Zhou et al (2020) based on complete follow -up of 191 in-hospital patients during the early 
outbreak of COVID -19 in China reported an in-hospital CFR as high as 28%, while other studies 
reported much 
smaller CFR with incomplete follow -up data. Detailed summaries of disease 
progression time course during hospitalization orby disease status based on large sample s, 
however, were no t found.
With this study  enrolling only hospitalized patients with COVID -19 induced pneumonia and 
CRS, and assuming that more than half of this patient population will likely  require invasive 
mechanical ventilation , the true response rate for the control arm of this study  is considered 
most likely  in the range from 20% - 5 0%, while the CFR is not likely to be more than 25%.
Invasive mechanical ventilation is a radical departure from the physiology  of breathing 
spontaneously , which put patients under risks of various immediate and long-term 
complications
(Soni and Williams 2008) regardless of thesurvival outcome .The benefits of 
canakinumab for COVID -19 patients is considered clinically  meaningful if it leads to an 
absolute increase of 15% patients who survived without ever requiring invasive mechanical 

Novartis Confidential Page 62of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
ventilation . A 4-week CFR reduction by half (i.e. relative risk=0.5) is also considered 
meaningful clinical benefit outweighing the known risks of canakinumab.
Assuming the true response rate for the control arm lies within the range of 
20% - 50%, a total 
sample size of 450 and 1:1 randomization ratio will provide at least 89% power to detect the 
minimum clinically  meaningful benefit of interest .
Table 12
-1 Power for primary analysis under vary ing assumptions (sample size = 
450)
Response Rate (%) Clinically meaningful benefits Power (2 -side 
α=0.05)Control ACZ885 difference OR RR
50 65 15 1.86 1.3 89%
40 55 15 1.83 1.38 89%
30 45 15 1.91 1.5 90%
20 35 15 2.15 1.75 94%
Earlydiscontinuation from study before patient recovery is considered unlikely in this study , 
hence the sample size is not adjusted forattrition . Blinded sample size reevaluation may be 
performed to confirm the assum ptions for the sample size calculation, based on which the 
sample size may  be updated without inflation of t ype I error.
12.7.2 Secondary  endpoint(s)
Using a hierarchical testing procedure for famil ywise 2-sided type I error control at 0.05, the 
hypothesis test in key  secondary  analy sis on 4 -week CFR will be performed if and only if null 
hypothesis in primary  analysis is rejected. 
The conditional power for detecting a 50% drop of 
4-week CFR are evaluated under different assumptions on control arm 4-week CFR .
Table 12-2 Power for key  secondary  analy sis (sample size = 450)
CFR (%) Clinically meaningful benefits Power (2 -side 
α=0.05)Control ACZ885 difference OR RR
25 12.5 -12.5 0.43 0.5 92%
20 10 -10 0.44 0.5 83%
15 7.5 -7.5 0.46 0.5 70%
Cases of lost to follow up before patient’s recovery  (clinical status = 0 or 1on the 9-point ordinal 
scale) and before Day 29 is expected to be minimal. Sample size adjustment for key  secondary 
analysis is not planned.
There is n
o formal hy pothesis test or power consideration for other secondary  anal ysis.

Novartis Confidential Page 63of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripar tite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Review Board/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, participa nt recruitment procedures (e.g., 
advertisements) and an y other written information to be provided to participants. Prior to study  
start, the investigator is required to sign a protocol signature page confirming his/her agreement 
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found in this protocol and to give access to a ll relevant data and records to Novartis 
monitors, auditors, Novartis Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority , the investigator must inform Novartis immediately  that this 
request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study  completion (defined as last patient last visit)
and finalization of the study report the results of this trial wil l be submitted for publication and 
posted in a publicly  accessible database of clinical trial results, such as the Novartis clinical trial 
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.).
For details on the Novartis publication policy  including authorship criteri a, please refer to the 
Novartis publication policy training materials that were provided to you at the trial investigator 
meetings.
13.4 Qualit y Control and Quality  Assurance
Novartis maintains a robust Quality  Management System that includes all activities involved in 
quality  assurance and quality  control, to ensure compliance with written Standard Operating 
Procedures as well as applicable global/local GCP regulations and ICH Guidelines.
Audits of inves tigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits a re conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes.

Novartis Confidential Page 64of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
14 Protocol adherence
This protocol defines the study  objectives, the study  procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safet y of participants should be 
administered as deemed necessary  on a case by case basis. Under no circumstances including 
incidental collection is an investiga tor allowed to collect additional data or conduct any 
additional procedures forany purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amend ment is agreed upon by Novartis 
and approved by the IRB/IEC and Health Authorities, where required, it cannot be implemented.
14.1 Protocol amendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for participant safety  may be implemented immediately  
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any  immediate action required for the safet y of any participant included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

Novartis Confidential Page 65of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
15 References
Available upon request
Ahn M, Anderson DE, Zhang Q, et al (2019) Dampened NLRP3 -mediated inflammation in 
bats and implications for a special viral reservoir host. Nature Microbiology; 4:789 - 99.
Alosaimi B, Hamad ME, Naeem A, et al (2020) MERS- CoV infection is associated with 
downregulation of genes encoding Th1 and Th2 cy tokines/chemokines and elevated 
inflammatory innate immune r esponse in the lower respiratory  tract. C ytokine; 126:154895.
Bauernfeind F, Ablasser A, Bartok E, et al (2011) Inflammasomes: current understanding and 
open questions. Cell Mol L ife Sci; 68:765 -83.
Beigel JH, Farrar J, Han AM, et al on behalf of the Writing Committee of the WHO 
Consultation on Human Influenza A/H5 (2005) Avian influenza A (H5N1) infection in 
humans. NEJM; 353:1374
-85.
Bouros D, Alexandrakis MG, Antoniou KM, et al (2005) The clinical significance of serum 
and bronchoalveolar lavage inflamma tory cytokines in patients at risk for acute respiratory  
distress sy ndrome. BMC Pulm Med; 4(6); doi: https://doi.org/10.1186/1471 -2466-4-6.
CDC (2020) Sy mptoms of Coronavi rus. (Internet) Available from: 
https://
.cdc.gov/coronavirus/2019- ncov/sy mptoms -testing/s ymptoms.html (Accessed 02 April 
2020).
CDC COVI D Response Team (2020) Severe Outcomes Among Patients with Coronavirus 
Disease 2019 (COVID -19) -United States, February  12–March 16, 2020. Morb Mortal Wkly  
Rep
; 69:343- 346. DOI: http://dx.doi.org/10.15585/mmwr.mm6912e2 .
Chen I -Y, Mori yama M, Chang M -F, et al (2019) Severe acute respiratory  syndrome 
coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol; 10:50.
Chen T, Wu D, Chen H, et al (202 0) Clinical characteristics of 113 deceased patients with 
coronavirus disease 2019: retrospective stud y. BMJ; 368:m1091.
Diao B, Wang C, Tan Y, et al (2020) Reduction and functional exhaustion of T cells in 
patients with coronavirus disease 2019 (COVID -19). medRxiv; doi: 
https://doi.org/10.1101/2020.02.18.20024364.
Fang Y, Xie H and Lin Z (2018) Association between IL-1β  + 3954C/T poly morphism and 
myocardial infarction risk: A meta -analysis. Medicine; 97(30):e11645.
Ganter MT, Roux J, Miy azawa B, et al (2008) Interleukin -1β causes acute lung injury  via 
αvβ5 and αvβ6 integrin -dependent mechanisms. Molecular Med; 102:804- 12.
Gasse P, Mary  C, Guenon I , et al (2007) IL -1R1/My D88 signaling and the inflammasome are 
essential in pulmonary  inflammation and fibrosis in mice. J Clin I nvest; 117(12):3786 -99.
Giavridis T, van der Stegen SJC, Ey quem J, et al (2018) CAR T cell -induced cy tokine release 
syndrome is mediated by macrophages and abated by  IL-1 blockade. Nat Med; 24:731-8.
Gorbalen ya AE, Baker SC, Bari c RS, et al on behalf of the Coronaviridae Study  Group of the 
International Committee on Taxonomy  of Viruses (2020) The species severe acute respiratory  

Novartis Confidential Page 67of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Mehta P, Mc Auley  DF, Brown M, et al (2020) COVID- 19: consider cy tokine storm 
syndromes and immunosuppression. Lancet; 395:1033 -4.
Min C -K, Cheon S, Ha N -Y, et al (2016) Comparative and kinetic anal ysis of viral shedding 
and immunological responses in MERS patients re presenting a broad spectrum of disease 
severit y. Sci Rep; 6:25359.
Norelli M, Camisa B, Barbiera G, et al (2018) Monocy te-derived IL -1 and IL -6 are 
differentiall y required for cytokine -release s yndrome and neurotoxicity due to CAR T cells. 
Nature Medicine; 24:739 -48.
Olman MA, White KE, Ware LB, et al (2004) Pulmonary  edema fluid from patients with 
early lung injury  stimulates fibroblast proliferation through IL- 1 beta -induced IL -6 
expression. J I mmunol; 172(4):2668 -77.
Park WY, Goodman RB, Steinberg KP, et al (2001) Cy tokine balance in the lungs of patients 
with acute respiratory  distress sy ndrome. Am J Respir Crit Care Med; 164:1896 -903.
Patton L M, Saggart BS, Ahmed NK, et al (1995) Interleukin- 1 beta -induced neutrophil 
recruitment and acute lung injury  inhamsters. Inflammation; 19(1):23 -9.
Perrone LA, Plowden JK, García -Sastre A, et al (2008) H5N1 and 1918 pandemic influenza 
virus infection results in earl y and excessive infiltration of macrophages and neutrophils in the 
lungs of mi ce. PLoS Pathog; 4(8):e 1000115.
Porter DL, Hwang WT, Frey  NV, et al (2015) Chimeric antigen receptor T cells persist and 
induce sustained remissions in relapsed refractory chronic l ymphocy tic leukemia. S ci Transl 
Med; 7(303):303ra139.
Porter D, Frey  N, Wood PA et al (2018) Grading of cy tokine release s yndrome associated 
with the CAR T cell therapy  tisagenlecleucel. J Hematol Oncol; 11(1):35.
Ridker PM, Everett BM, Thuren T, et al CANTOS Trial Group (2017) Antiinflammatory  
Therap y with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine; 
377(12):1119-31.
Schmitz N, Kurrer M, Bachmann MF, et al (2005) Interleukin- 1 is responsible for acute lung 
immunopathology  but increases survival of respiratory  influenza virus infection. J Virol; 
79(10):6441-8.
Schuster SJ, Svoboda J, Chong EA, et al (2017) Chimeric Antigen Receptor T Cells in 
Refractory  B-Cell Ly mphomas. New England Journa l of Medicine; 377(26):2545 -54.
Soni N and Williams P (2008) Positive pressure ventilation: what is the real cost? British J 
Anaesthes ia; 101.4:446- 57.
Thevarajan I, Ngu yen THO, Koutsakos M, et al (2020) Breadth of concomitant immune 
responses prior to patient recovery: a case report of non- severe COVID -19. Nature Medicine; 
doi: https://doi.org/10.1038/s41591-020-0819-2.

Novartis Confidential Page 68of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Toldo S, Mezzaroma E, Bressi E, et al (2014) Interleukin -1β blockade improves left 
ventricular s ystolic/diastolic function and restores contractility  reserve in severe ischemic 
cardiom yopath y in the mouse. J C ardiovasc Pharmacol; 64(1):1 -6.
Tumpey  TM, Basler CF, Aguilar P V, et al (2005) Characterization of the reconstructed 1918 
Spanish influenza pandemic virus. Science; 310(5745):77-80.
Wan S, Yi Q, Fan S, et al (2020) Characteristics of ly mphocy te subsets and cy tokines in 
peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). 
medRxiv; doi: https://doi.org/10.1101/2020.02.10.20021832.
Wang W, He J, L ie P, et al (2020) The definition and risks of cy tokine release s yndrome -like 
in 11 COVI D-19-infected pneumonia criticall y ill patients: disease characteristics and 
retrospective anal ysis. medRxiv; doi: https://doi.org/10.1101/2020.02.26.20026989 .
WHO (2020a ) Novel Coronavirus(2019 -nCoV) Situation Report – 22. (Internet) Available 
from < https://.who.int/docs/default -source/coronaviruse/situation- reports/20200211 -sitrep-22-
ncov.pdf?sfvrsn=fb6d49b1_2> (Accessed 01 April 2020).
WHO (2020b) Novel coronavirus, COVID -19 Therapeutic Trial Synopsis. World Health 
Organization R&D Blueprint; dated 18-Feb- 2020.
Worldometers (2020) COVID -
19 Coronovirus Pandemic. (Internet) Available from 
<https://
.worldometers.info/coronavirus/> (Accessed 28 March 2020).
Wu Z and McGoogan JM (2020) Characteristics of and important lessons from the 
coronavirus disease 2019 (COVID -19) outbreak in China: summary  of a report of 72314 cases 
from the Chinese Center for Disease Control and Prevention. JAMA; Published online Feb 
24. DOI:10.1001/ jama.2020.2648.
Xu H, Zhong L, Deng J, et al (2020) High expression of ACE2 receptor of 2019-nCoV on the 
epithelial cells of oral mucosa . Intl J of Oral Sci; 12:8; doi: https://doi.org/10.1038/s41368 -
020-0074- x.
Xu X, Han M, Li T, et al (2020) Effective Treatment of Severe COVID -19 patients with 
Tocilizumab. chinaXiv:202003.00026v1.
Zhang H, Luo J, Alcorn JF, et al (2017) AIM2 inflammasome is critical for influenza -induced 
lung injury  and mortalit y. J I mmunol; 198(11):4383 -
93.
Zhao C and Zhao W (2020) NL RP3 inflammasome –a key  play er in antiviral responses. 
Front Immunol; 11:211; doi: 10.3389/fimmu.2020.00211.
Zhao D, Yao F, Wang L, et al (2020) A comparative study  on the clinical features of COVID -
19 pneumonia to other pneumonias. Clin I nfect Dis; doi: ciaa247. doi:10.1093/cid/ciaa247.
Zheng HY, Zhang M, Yang CX, et al (2020) Elevated exhaustion levels and reduced 
functional diversity  of T cells in peripheral blood may  predict severe progression in COVI D-
19 patients. Cell Mol I mmunol; doi: 10.1038/s41423 -020-0401-3.

Novartis Confidential Page 69of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Zhou F, Yu T, Du R, et al (2020) Clinical course and risk factors for mortality  of adult 
inpatients with COVI D-19 in Wuhan, Ch ina: a retrospective cohort stud y. Lancet; doi: 
https://doi.org/10.1016/S0140- 6736(20)30566-3.

Novartis Confidential Page 70of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
16 Appendices
16.1 Appendix 1: Ordinal Scale Determination
The ordinal scale is an assessment of the clinical status at the first assessment of a given study 
day. Each d ay, the worse score for the previous day will be recorded. i.e. on Day 3, Da y 2 score 
is obtained and recorded as Day  2.
The scale is as follows:
Patient State Descriptor Score
Uninfected No Clinical or virological evidence of infection 0
Ambulator yNo limitation of activities 1
Limitation of activities 2
Hospitalized
Mild diseaseHospitalized, no ox ygen therapy 3
Oxygen by mask or nasal prongs 4
Hospitalized
Severe diseaseNon-invasive ventilation or high- flow oxygen 5
Intubation and mechanical ventilation 6
Ventilation + additional organ support -
pressors, RRT, ECMO 7
Dead Death 8
(WHO 2020b )

Novartis Confidential Page 71of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
16.3 Appendix 3: Liver event and laboratory trigger definitions & 
follow -up requirements
Table 16-1 L iver event and laboratory  trigger definitions
Definition/ threshold
Liver laboratory triggers
IfALT, AST and tota l bilirubin normal at 
baseline:ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone 
pathology)
Total bilirubin > 3 × ULN (in the absence of known 
Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s L aw cases (defined as ALT or AST > 3 
× ULN and Total bilirubin > 2 × ULN [mainly conjugated 
fraction] without notable increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
Any adverse event potentially indicative of a liver 
toxicity*
If ALT or AST abnormal at baseline: ALT or AST > 3x baseline or > 300 U/L (whichever is 
higher )
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms ULN: 
upper limit of normal

Novartis Confidential Page 72of 72
Amended Protocol Version 01 (Clean) Protocol No. CACZ885D2310
Table 16-2 Follo w up requirements for liver labo ratory  triggers
Criteria Actions required Follow -up monitoring
Total Biliru bin (isolated)
>1.5 –3.0 ULN Repeat LFTs within 48 -72 
hoursMonitor LFTs weekly until 
resolutionato ≤ Grade 1 or to 
baseline
> 3 -10 × ULN (in the absence 
of known Gilbert s yndrom e)Repeat LFT within 48 -72 
hours
Establish causality
Record the AE and 
contributing factors (e.g. 
conmeds, med hx, lab) in the 
appropriate CRFMonitor LFTs weekly until 
resolutioncto ≤ Grade 1 or to 
baseline (ALT, AST, total 
bilirubin, Alb, PT/INR, ALP and 
GGT)
Test for hemoly sis (e.g. 
reticulocytes, haptoglobin, 
unco njugated [indirect] 
bilirubin)
> 10 x ULN Establish causality
Record the AE and 
contributing factors(e.g. 
conmeds, med hx, lab)in the 
appropriate CRFALT, AST, total bilirubin, Alb, 
PT/INR, ALP and GGT until 
resolutiona(frequency at 
investigator discretion)
Any AE potentially indicative of 
a liver toxicity*Hospitalization if clinically 
appropriate
Establish causality
Record the AE and 
contributing factors(e.g., 
conmeds, med hx, lab)in the 
appropriate CRFInvesti gator discretion
aResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) 
stable values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated 
level after a maximum of 6 months, (4) liver transplantation, and (5) death.
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms ULN: 
upper limit of nor mal
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can include: Serology  tests, imaging and pathology  assessments, hepatologist’s consultancy ; 
obtaining more detailed history  of symptoms and prior or concurrent diseases, history  of 
concomitant drug use, exclusion of underl ying liver disease.
